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Chapter 1
Introduction and outline of the thesis
Chapter 1
Past-to-present
In 1963, Laurell and Eriksson, presented in the "Scandinavian Journal of Clinical 
and Laboratory Investigation" 5 patients with a new type of dysproteinemia, 
characterized by very pronounced a lp h a-i antitrypsin (A iA T) deficiency. This 
deficiency was detected by paper electrophoresis. (Figure 1.1) A total of 3 out of 
these 5 patients had pulmonary disease, 1 patient had a malabsorption syndrome 
and the last patient had no obvious disease.1
Figure 1 .1 : Diagnostic tools in 1 9 6 3 .
Paper electrophoretic protein pattern o f sera 
from tw o patients w ith  a lp h a -i antitrypsin  
deficiency and from a control. (Upper and lower: 
cases; Middle: control)1
Agar gel electrophoresis o f serum from a patient 
and from a normal control. (Uppercase and lower: 
control)1
In 1967 and 1970, they continued to establish an association between chronic 
obstructive lung disease and A iA T  deficiency.2-3 In 1972 these authors 
published a key paper that described the presence of liver disease in adults 
with A iA T  deficiency4and in ig 74 th e y  reported a high incidence of hepatocel­
lular carcinoma in patients with A iA T  deficiency related cirrhosis.5 At that 
time, others showed A iA T  polymers in 52% of hepatocellular carcinom a6 and 
furthermore, A iA T  deficiency was considered as a cause of neonatal hepatitis.7 
The first report on A iA T  deficiency originating from the Netherlands was pub­
lished in 1980 and contained interesting epidemiologic data that demonstrated 
that the frequency of A iA T  deficiency was 8 out of 10,000 newborns.8 In 1983 
the point mutation which is involved in A iA T  deficiency was detected.9 
Over the years, many reports concerning A iA T  deficiency and its relation
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with prognosis, associations with environmental factors, (patho)physiologic 
mechanisms and gene association studies have been published. In December 
2009, a "Google-search" for A iA T  deficiency resulted in no less than 1.3 million 
hits. Nowadays, the diagnosis A iA T  deficiency is not made by a paper patchy 
spot as shown above, but current diagnostic tools are much more sophisticated. 
(Figure 1.2 and 1.3)
RRI for Allele 1 
FAM-490
A: BioRad ¡Cycler 
B: Melting curve 
C: Allelic discrimination figure
Figure 1 .3 : Real-Time PCR for 
m utation detection.
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The gene
A iA T  deficiency is a genetic disorder and the AiATprotein is encoded by the 
protease inhibitor (Pi) locus located on chromosome i4 q 3 2 .i (S E R P IN A i- 
gene). The A iA T  protein is a member of the "SERPIN" family, similar to 
alphai- antichymotrypsin, alpha2-antiplasmin, antithrombin and Ci-inhibitor. 
The gene is 12.2 kb in length with 7 exons (4 coding and 3 non-coding) and 
6 introns. (Figure 1.4) The protein encoded includes 394 amino acids. The 
protease inhibitor locus is highly polymorphic with approxim ately 123 single 
nucleotide polymorphisms (SNPs), resulting in numerous different A iA T  
isotypes that can be detected by iso-electrophoresis. The wild type allele 
results in a normal M-type protein. The most common mutations are E264V  
and E342/C, resulting in the S-type protein (exon 3) and Z-type protein (exon 5) 
respectively. Beside the SNPs in exons, other SNPs in the enhancer sequence 
of the A iA T  gene, involving the regulation of A iA T  expression have been 
described.10-11
Figure 1 .4 : schematic overview o f the SER PIN A i gene.
E264V E342K
I [
Exort 1A Exon IB  1C Exon 2 Exon 3 Exon4 Exo n s 3'«rhanc«r
— M i -------------B i l l
1 2  3 4  5 6 7 8 9
--------- H-----------1------------------------------- 1-----------1-------------- 1------¥
The protein
A iA T  is mainly produced in the liver and reaches the lung by diffusion from 
the circulation or by pulmonary production in macrophages and bronchial 
epithelial cells.12The A iA T  protein is a serum glycoprotein acting as an acute 
phase protein. The major physiological function of A iA T  is inhibition of 
proteolytic enzymes as elastase and other proteinases which are secreted by 
neutrophilic granulocytes during inflammatory processes. The normal A iA T  
protein has a tertiary structure based on a large central il-sheet, surrounded
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by two other sheets and a reactive centre loop. The reactive centre loop binds 
to proteinases and can move in and out the il-sheet. In case of a Z-type protein 
(thus E342K  mutation) the reactive centre loop is reacting with the il-sheet of 
a second A iA T  molecule. As a consequence, this leads to polymers that are 
retained in the endoplasmic reticulum of hepatocytes.n '13 (Figure 1.5)
Figure 1 .5 : Loop sheet polym erization due to  Z m utation in A iA T  deficiency.
A: destabilization of the IS-sheet due to Z-type AIAT. B: insertion of the reactive loop of 
another AIAT molecule leads to dimer formation and C: subsequently formation of 
polymers. (From: Ned Tijdschr Geneeskd 2003;147(16):758-60, with permission)
Mechanism of liver disease
Several studies have provided evidence that the SNP, which is responsible 
for the Z-type A iA T  reduces the stability of the molecule in its monomeric 
form and increases the likelihood that it will form polymers by a so-called 
"loop-sheet" insertion mechanism .14 Z-type A iA T  polymers can be identified 
by electronm icroscopy as periodic-acid-Schiff stain positive and diastase- 
resistant inclusions within the endoplasmic reticulum of hepatocytes. (Figure 
1.6 panel B) The S-type A iA T  has less effect on loop sheet polymerization 
and accumulation. It is suggested that the process of protein degradation 
involves modification of misfolded proteins by the enzyme endoplasmic 
reticulum m annosidase I. Mannosidase inhibitors delay degradation and 
increase secretion of Z-type AiAT. Expression of liver disease in patients with
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A iA T  deficiency correlates with a delay in intracellular degradation of Z-type 
A iA T  and accumulation of polymers. There is remarkable variability in the 
phenotypic expression of disease in individuals with Pi ZZ hom ozygosity.12 
Apart from environmental factors such as smoking and alcohol abuse, genetic 
modifiers appear to be partly responsible for the variability in clinical expression 
of patients with A iA T  deficiency. For example, SNPs in the promoter region 
and a variant of the endoplasmic reticulum mannosidase I (ERManl) gene were 
associated with an early onset of end-stage liver disease in patients with 
homozygous (Pi ZZ) A iA T  deficiency.15-16 Others suggested that individual 
variations in episodes of inflammation and hence to increased synthesis of 
A iA T can explain the variability in severity of liver disease and its age at onset.17
Mechanism of pulmonary disease
Polymerization and retention of polymers in the endoplasmic reticulum of 
hepatocytes, causes a decrease in the amount of serum A iATthat is available 
to protect the lungs against elastolytic dam age.17 An imbalance between the 
A iA T  protection and elastase with consequent unchecked proteolytic activity, 
can lead to emphysema. Either a mild increase in elastase (which might happen 
with smoking or lung infection) or a reduction in anti-elastase defence (which 
may happen in severe A iA T  deficiency) can affect the elastase-anti-elastase 
balance unfavourably towards accelerated lung breakdown.12 (Figure 1.6, panel 
A) The decreased A iA T  level is not a single issue, the Z-type A iA T  is about 
5 time less effective as an inhibitor of elastase than normal M-type A iA T .18 
In addition, Z-type A iA T  polymers might be chemoattractants for neutrophils 
thereby potentially increasing lung inflam m ation.19
Outline of the thesis
Despite progress in understanding the mechanisms of disease in A iA T  
deficiency, several questions with regard to the clinical consequences of A iA T  
deficiency are still open.
First, we are interested in the clinical course of A iA T  deficiency. What is the 
course of liver disease in A iA T  deficiency with respect to the pediatric and
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adult population? Are there specific com plicationsthat need to be considered 
when treating these patients? Second, we will focus on the diagnostic strategy 
for establishing A iA T  deficiency. Third, we wonder whether SNPs in the 
SERPIN A i gene modify the development, course, and treatment results of liv­
er diseases due to various etiologies. Finally, we addressed questions 
regarding the clinical relevance of liver disease due to heterozygous A iA T  
deficiency.
This thesis aims to address these issues with a primary focus on the elements 
that are important for the clinical management of these patients.
Figure 1.6: Mechanisms of pulmonary and liver disease.
Lung parenchyma viewed 
with light microscopy 
------- 17
I
V-
Enlarged
alveolar
Lung with predominantly 
basifarpanacmar 
emphysema in AAT deficiency
Alveoli with panacinar destruction 
and enlargement
Liver affected by AAT
Polymerized AAT 
molecules in a single granule
Panel A: mechanism for the developm ent o f emphysema in patients w ith  A iA T  deficiency.
Panel B: overview o f liver disease in patients w ith A iA T  deficiency, (from: NEJM20og;3 6 o(2 6 ):27Z,.9 , 
w ith  permission)
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Abstract
A lp h a-i antitrypsin (A iA T) is an acute phase protein that 
is produced in liver cells. A iA T  deficiency is a hereditary 
disease that is defined by the hepatic production of an 
abnormal protein that cannot be released into the plasma. 
This leads to deficiency of plasma A iA T  and subsequently 
to an impaired protection against proteases, resulting in 
pulmonary disease. Accumulation of the abnormal protein in 
hepatocytes can lead to liver damage. Serum level mea­
surement, phenotyping and liver biopsy can be used for 
establishing the diagnosis.
Homozygous A iA T  deficiency can cause neonatal hepatitis; 
in adults end stage liver disease, cirrhosis and hepatocellular 
carcinoma may develop. There are strong arguments to 
consider heterozygous A iA T  deficiency as an important 
co-factor in the etiology of chronic liver disease. Studies 
have shown that A iA T  heterozygosity can be considered 
a modifier for HCV, end stage live disease, cirrhosis and 
hepatocellular carcinoma. The accumulation of A iA T  in 
the hepatocytes occurs more profoundly in a sick liver, and 
as a consequence it affects the natural course of the liver 
disease.Therapeutic options include augmentation therapy 
(infusion of purified human plasma A iA T ) in pulmonary 
disease; in end stage liver disease livertransplantation is an 
option. In the future other interventions such as gene ther­
apy or strategies to inhibit polym erization are promising.
A 1A T d e f ic ie n c y  a nd  c h ro n ic  l iv e r  d is e a s e : re v ie w
Background
A lp h a-i antitrypsin (A iA T) is an acute phase protein that is produced in liver 
cells. It is released into the plasma in response to an inflammatory stimulus. 
A iA T  deficiency is a hereditary disease that is defined by the hepatic production 
of an abnormal protein that can not completely be released into the plasma. 
This leads to deficiency of plasma A iA T  and subsequently to an impaired pro­
tection of the lungs against proteases. This results in pulmonary emphysema, 
the hepatic accumulation of the abnormal protein can lead to chronic liver 
disease.This review gives an update of the present knowledge of partial A iA T  
deficiency in relation to various liver diseases.
Genetics and (patho) physiology
The A iA T  molecule is a serum glycoprotein acting as an acute phase protein. 
It is released during inflammatory processesfrom  the hepatocyte which results 
in increased plasma concentrations. The major physiological function of this 
protein is the inhibition of destructive neutrophil elastase, thus protecting against 
pulmonary dam age.1 The A iA T  protein is encoded by the protease inhibitor 
(PI) locus located on chromosome i4 q 3 2 .i.T h e  PI locus is highly polymorphic, 
resulting in different A iA T  isotypes that can be detected by electrophoresis. 
The most common allele is the M allele that results in a functionally normal 
protein with normal serum A iA T  levels. The normal A iA T  protein has a tertiary 
structure based on a large central il-sheet, surrounded by two other sheets and 
a reactive centre loop.The reactive centre loop can move in and out of the large 
il-sheet. At highertem peratures polymerization can occur between molecules 
due to insertion of the loop of one molecule into the large il-sheet of the other. 
The point mutation, found in the Z variant destabilizes the loop-sheet poly­
merization of the A iA T  molecule, resulting in chains of polymers that are 
retained in the hepatocytes. These polymers accumulate in the endoplasmic 
reticulum of the hepatocytes and may be recognized as PAS(+) inclusion 
bodies. (Figure 2.1) Only 15% of the Z-variant of A iA T  can be secreted into 
the plasma, the other 85 % accumulates in the liver. In Pi ZZ homozygous 
subjects, this results in a severe deficiency of serum A iA T  and in accumulation 
of the abnormal protein in the endoplasmatic reticulum of the hepatocyt 
which can lead to chronic liver disease.
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The S variant of the A iA T  molecule, has less effect on the loop sheet poly­
merization. Formation of S-polymers is slower, resulting in less retention 
of protein in the hepatocytes compared to the Z variant. There is a mild 
reduction in serum A iA T  levels. When S and Z variants are co-inherited, the 
two interact with the formation of polymers within the hepatocytes; this 
can lead to reduction in the serum A iA T  level, inclusion of the polymers, 
accumulation and subsequently development of cirrhosis.
Less frequently found variants are null alleles resulting in undetectable A iA T  
levels due to intracellular degradation or intracellular accumulation of the 
protein; this is usually associated with severe pulmonary disease, but not with 
liver disease.2-7 (Table 2.1)
Table 2.1: Characteristics of the different A iA T  alleles
Allele Mutation Cellular defect Enzymatic
activity
M - - Normal
S Glu264Val Intracellular
degradation
Intermediate
z Glu342Lys Intracellular
accumulation
Low
Null Different
mutations
Most mutations no 
mRNA
Nili
A iA T  deficiency is characterized by an imbalance between the protease 
neutrophil elastase and the protease inhibitor AiAT. It has been suggested 
that neutrophil elastase might promote the developm ent of cancer.8 The 
exact carcinogenic mechanism or sequence is not known.
In a recent paper, the authors hypothesized, that in A iA T  deficiency, the hepa­
tocytes in which A iA T  is accumulated are inhibited in their growth, but still do 
express regenerative signals. Relatively normal cells, without A iA T  deposits 
are thereby stimulated and this chronic stimulation of regeneration may lead 
to the formation of neoplasmata.9
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Diagnostic aspects
To establish the diagnosis different methods are available. The A iA T  serum 
level can be determined by clinical chemistry. In homozygous A iA T  deficiency 
the level is very low. However in the heterozygous variant the A iA T  level 
can be within the normal range, especially during an acute phase reaction. 
Therefore electrophoresis should be performed in any case of suspected 
A iA T  deficiency in order to determine the phenotype. Liver biopsy is the 
gold standard for establishing A iA T  accumulation and PAS positive, diastase 
resistant inclusions can be found. A specific immuno-histochemical staining 
can confirm the diagnosis. (Figure 2.1) It is also possible to determ ine the 
phenotype on paraffin embedded liver slides.
Figure 2 .1  Liver biopsy: cirrhosis due to  a lp h a -i antitrypsin deficiency.
A: HE-staining, 2ox: micro nodular liver cirrhosis B: D-PAS staining, 4 . 0 X :  Diastase resistant, Periodic- 
Schiff-Acid positive globuli, matching w ith  A iA T  accumulation C: A iA T  antibodies, 4 . 0 X :  confirm ation  
of A iA T  accumulation
21
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Epidemiology
Despite the fact that A iA T  deficiency is a frequent disorder, it is poorly recog­
nised in clinical practice. There are probably two main reasons, first in patients 
with liver disease, the diagnosis is not always considered and second not all 
subjects with a deficient phenotype develop liver disease, i.e. the penetrance 
is low.10
Given this well known underdiagnosis, the real prevalence of A iA T  deficiency 
has mainly been determined by epidemiological methods, either using a control 
cohort from an epidemiological study, or through neonatal screening. The Z- 
allele is especially prevalent in Northern Europe, while the S allele is prevalent 
in Southern Europe (Table 2.2)
Table 2 .2 : E pidem iology*10 15*
Country
PiZZ
Frequency
PiMZ PiSZ
Method Year
Sweden 0,06% - 0,03% Neonates, phenotyping if serum AIAT < 40% 1976
The Netherlands Z allele _ S allele Neonates, phenotyping when 1980
0,03% 0,04% AlAT/transferrine < 1,2
France 0,01% 2% 0,15% Control cohort epidemiological study 2003
Spain 0,01% - 0,2% Control cohort epidemiological study 2003
Italy 0,02% 2,4% 0,06% Control cohort epidemiological study 2003
Portugal 0,02% 2,3% 0,3% Control cohort epidemiological study 2003
Australia 0,02% 2,5% 0,12% Control cohort epidemiological study 2003
USA 0,02% 2,7% 0,09% Control cohort epidemiological study 2003
New Zealand 0,05% 4,3% 0,17% Control cohort epidemiological study 2003
Canada 0,02% 2,7% 0,11% Control cohort epidemiological study 2003
Clinical aspects
Pulmonary disease
A iA T  deficiency is associated with less inhibition of elastase resulting in pulmo­
nary disease. A iA T  homozygosity (Pi ZZ) results in a pulmonary phenotype with 
early onset of emphysema, asthma and bronchi ectasia. A iA T  deficiency results 
in panacinar pathology and disproportionate emphysematous involvement
A 1A T d e f ic ie n c y  a n d  c h ro n ic  l iv e r  d is e a s e : re v ie w
of the lung bases. Tobacco smoking is the most important additional risk- 
factor for the development of pulmonary disease. Also subjects with the 
Pi MZ phenotype have an increased risk for the development of pulmonary 
disease.7
Neonatal / paediatric liver disease
AIAT deficiency is the most common genetic cause of liver disease in early 
childhood. The most common presentation is by prolonged jaundice. The 
stools generally contain no yellow or green pigment, indicating cholestasis 
and mimicking biliary atresia. All patients have hepatomegaly and about 50% 
also have splenomegaly. Approximately 5% of the patients present with an 
increased bleeding tendency. This is due to vitamin K deficiency caused by the 
cholestasis induced malabsorption. Less commonly children present later in 
childhood with hepato-splenomegaly or with cirrhosis.16-19 
In Sweden, in 1972-1974 200,000 neonates were screened for A iA T  deficiency: 
120 Pi ZZ (0,06%), 2 Pi Z-, 54 Pi SZand 1 Pi S- children were found. Only 14 of the 
Pi ZZ children had prolonged jaundice, 9 of those had severe liver disease. All 
infants appeared healthy at six months of age. Infants with a Pi SZ phenotype 
had no signs of liver disease.
At the age of 16 years, in 17% of Pi ZZ adolescents and in 8% of Pi SZ adolescents, 
elevated liver enzymes were found.The adults with liver disease in infancy were 
clinically healthy. At the age of 26 years, the Pi ZZ subjects were compared to 
Pi MM individuals.The Pi ZZ subjects had normal lung function; 4-9% of them 
had mild livertest abnormalities.10-20-21 In the Province of Bozen in Northern Italy, 
Pi phenotyping in umbilical cord blood was performed as a routine neonatal 
screening. About 5% of Pi SZ children were affected by liver involvement with 
elevated liver enzymes and 7% of 833 Pi MZ heterozygotes had elevated liver 
enzymes in early childhood. At age of 5 and 10 years, none had liver disease. 
The serum levels of A iA T  were similar in the groups with and without liver 
test abnorm alities; however these values had a wide range.22-23 Although 
these studies suggest a good prognosis for neonatal cholestasis due to 
AiAT-deficiency, other studies described children who developed severe liver 
disease.16-19
23
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Liver disease in homozygous A iA T  deficient adults
Liver disease due to A iA T  deficiency generally presents at adult age. One 
study reviewed adult patients with liver disease and A iA T  deficiency; the 
mean age of the patients when liver disease became symtomatic was 58 years 
for the ZZ phenotype, 66 years for the SZ phenotype and 73 years for the MZ 
phenotype. If the liver disease was advanced at the time of diagnosis, 42% of 
these patients died within two years.24 A review of autopsy data on 94 Pi ZZ 
homozygous A iA T  carriers showed that cirrhotic patients survived longer 
compared to non-cirrhotic patients. The non-cirrhotic patients had more 
severe lung disease and died earlier.25 A cohort of patients who are registered 
in the A lp h a-i foundation Registry (a USA foundation providing increased 
research and improved health for A iA T  deficiency), and who had reported liver 
disease or jaundice (165 of the 2175 participants in the registry) completed 
a questionnaire. Of these patients 71% was Pi ZZ and 18% was Pi MZ, in the 
rem ainder the phenotype was unknown. Mean age at diagnosis of liver 
disease was 31 years (range 0-68 years), 30% had had livertransplant or were 
on the waiting list. Male gender and obesity were risk factors for advanced 
liver disease, while white race, Pi phenotype, infant jaundice, diabetes or 
hypercholesterolemia were not.26 Although this survey is the largest cohort of 
A iA T  deficiency and liver disease in the literature, the self-selected cohort 
runs a risk of inclusion bias. The natural history of the disease is not completely 
known. The risk of cirrhosis in adults is difficult to estim ate because most 
available data are retrospective and derived from patients known to have 
A iA T  deficient lung disease or cirrhosis.27-28
Heterozygous A iA T  deficiency and liver disease
Although the role of homozygous A iA T  in liver disease is established, the 
association between heterozygous A iA T  deficiency and chronic liver disease 
is still subject to ongoing investigation. Several studies however showed an 
association between heterozygous A iA T  deficiency and chronic liver disease. 
In 1981 a study showed the association of Pi MZ and liver disease. A total of 
1055 liver biopsies was screened for A iA T  depositions in hepatocytes and 34 
patients with this inclusions were found. These patients were phenotyped, the
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prevalence of phenotype Pi MZ in the whole biopsy group was 2.4%. In 
the subgroup of patients with liver cirrhosis, 9% had a Pi MZ phenotype. 
A percentage of 21 % of patients with cryptogenic cirrhosis and chronic 
hepatitis had a Pi MZ phenotype. This was significantly increased compared to 
other causes of cirrhosis. The prognosis of the Pi MZ cirrhotic patients was 
poor, most patients died within one year.29 More recently patients with end 
stage liver disease, in work-up for liver transplantation were investigated. 
Pi MZ was found in 7.3- 8.2%, compared to 2.8%  in the control population. 
A heterozygous phenotype was more prevalent in patients with hepatitis C, 
alcoholic liver disease, cryptogenic cirrhosis and hepatocellular carcinom a.30-31 
In one study consecutive liver biopsies and autopsies were screened for Pi Z 
deposits. In the biopsy group 3.4% of cases were Pi MZ phenotyped, whereas 
in the autopsy group this was 1.8%. In biopsies from older people heterozygous 
for AiAT, more fibrosis and more Pi Z deposits were found; the liver involvement 
seems to be age dependent. In case of coexisting liver disease, patients pre­
sented with more inflammation, more fibrosis and more Pi Z deposits than 
the biopsies without concomitant liver disease.32 We described 3 patients with 
alcoholic liver disease and a rapidly deteriorating clinical course, resulting in 
the patients' death. All 3 patients were found to be heterozygous for A1AT.33 
To summarize: These studies showed that various liver diseases influence the 
A iA T  accumulation and that the A iA T  accumulation influences the course of 
the liver disease. The risk of developing liver cirrhosis is increased in patients 
with heterozygous A iA T  deficiency, also without coexisting liver disease. The 
exact impact and involvement of liver disease by heterozygous A iA T  deficiency 
are unknown. Further research is needed to provide these data.
Heterozygous A iA T  deficiency and coexisting hepatitis C virus infection
The role of A iA T  deficiency in the severity and the course of liver disease 
in chronic hepatitis C virus (HCV) infection is not clear, despite the fact that 
several studies analyzed the association of HCV-induced liver disease and 
A iA T  deficiency. In Austria 1865 patients referred for the evaluation of chronic 
liver disease were analyzed, 9% had a deficient phenotype. From these 
patients with cirrhosis, 62% was HCV positive, 33% had evidence for HBV
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infection, 41% abuse of alcohol and 12% had features of autoimmune liver 
disease. Out of 53 cirrhotic A iA T  deficient patients, only 5 had no coexisting 
liver disease. The authors concluded that the risk for chronic liver disease is 
increased in patients with the Pi Z gene, because they may have increased 
susceptibility to viral infection or additional factors, necessary to induce 
chronic liver disease.34 The same authors investigated the prognosis of 
patients with A iA T  deficiency. Some 54 patients with A iA T  deficiency had 
evidence of chronic liver disease, 78% showed positive viral markers (hepatitis 
B or hepatitis C); this was compared to 106 patients with A iA T  deficiency 
without chronic liver disease, without signs of additional viral infection. Life 
expectancy in A iA T  deficient patients was significantly lower in patients with 
chronic liver disease in comparison to patients without chronic liver disease.35 
Patients with end stage liver disease, in work-up for livertransplantation were 
also investigated. In the HCV patients Pi MZ was found in 10-13%, compared 
to 2,8% in the control population. This suggests that an abnormal heterozygous 
phenotype is a co-factor in the development of chronic liver disease in HCV.30-31 
In contrast, other studies showed no association of hepatitis C infection and 
A iA T  deficiency.36-38
To conclude: the results of these studies are controversial. Some studies 
showed a higher incidence of A iA T  deficiency in HCV infection and an 
increased susceptibility to viral infections in A iA T  deficiency and other studies 
do not. Different methods to determine the A iA T  state were used. Further 
research on the influence of A iA T  deficiency in the course of HCV infection 
and vice versa is necessary.
Heterozygous A iA T  deficiency and hepatocellular carcinoma
Established risk factors for hepatocellular carcinoma (HCC) include amongst 
others chronic hepatitis B, HCV infection and alcoholic liver cirrhosis. Several 
studies investigated the correlation between A iA T  deficiency and HCC.39-40 In 
1986 it was suggested fo rthe first time that men with A iA T  deficiency may be 
at risk for cirrhosis and HCC. Autopsy was performed in 16 adult patients with 
A iA T  deficiency. In 5 out of these 16 patients, a HCC was found.40-41 In 317 
HCC, Pi Z deposits were found in 6% compared to 1.8% in the control group.
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In heterozygous A iA T  deficiency, HCC had also developed in non-cirrhotic 
livers and were frequently characterized by cholangiocellular differentiation. 
In patients with A iA T  deficiency bile duct lesions were frequently found. 
This might reflect a predisposition for the liver tissue for developing tumours 
with cholangiolar differentiation in A iA T  deficiency.43-44 In contrast to these 
studies, others did not show an association between A iA T  deficiency and 
hepatocellular carcinoma, although carcinomas in non-cirrhotic livers were 
Pi MZ associated.45-48
To summarize: several studies are performed to investigate the relation between 
A iA T  deficiency and hepatocellular carcinoma. The outcomes are not uniform. 
In our opinion studies with large cohorts of patients with hepatocellular carci­
noma are the most reliable; these studies did find an association.
A iA T  deficiency and associations with other diseases
A iA T  deficiency is not only associated with liver and lung disease. Associations 
with panniculitis, nephrotic syndrom e, intracranial aneurysm, hereditary 
haemochromatosis and celiac disease have been described.49-62
Therapy
Most therapeutic strategies in the treatm ent of A iA T  deficiency are directed 
towards pulmonary disease. Infusion of purified pooled human plasma A iA T is  
known as augmentation therapy. The goal of this treatm ent is to raise and 
maintain serum A iA T  concentrations above the protective threshold. Data from 
different studies suggest that intravenous augmentation therapy has a positive 
biochemical and clinical effect.The therapy is expensive (US $ 28,075-65,973 per 
year).7 Different concepts have been studied to prevent the polymerization 
and accumulation of the A iA T  protein. New peptides that block the poly­
merization of the Z protein have been developed.63-64 Gene therapy by injecting 
adeno-associated virus carrying the human A iA T  gene is another promising 
concept.65 Livertransplantation is used in end stage liver disease and results in 
acquisition of the donor phenotype, a rise in serum levels of A iA T and prevention 
of associated diseases.66
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Conclusion
A lp h a-i antitrypsin deficieny is an autosomal recessive disorder that can 
lead to chronic pulmonary disease and liver disease.The liver disease is caused 
by accumulation of an abnormal, polymerized protein. Deficient phenotypes 
are present worldwide. Homozygous A iA T  deficiency in children can cause 
neonatal hepatitis. In adults homozygous patients are at risk for developing 
end stage liver disease, cirrhosis and hepatocellular carcinoma. Heterozygous 
A iA T  deficiency is probably an important co-factor in the etiology of chronic 
liver disease, as several studies showed associations with HCV, end stage 
liver disease, cirrhosis and HCC. Screening on A iA T  deficiency should be 
done routinely, A iA T  serum levels may be used, but phenotyping is crucial, 
as serum levels may be not reflect true deficiencies (due to inflam m ation 
serum levels can be false normal). Especially in cryptogenic chronic liver dis­
ease and in liver disease that deteriorates faster than may be expected, A iA T  
deficiency may be of clinical significance as a (co)-factor. Clinical research is 
needed in AiAT-related liver disease to investigate the association between 
heterozygous A iA T deficiency and the presentation and course of liver diseases.67 
We believe that current data are insufficient to decide on the pro's and con's of 
screening on hepatocellular carcinoma in A iA T  deficiency.Therapeutic options 
in A iA T  deficiency include augm entation therapy in pulm onary disease; in 
end stage liver disease liver transplantation is an option. Gene therapy or 
strategies to inhibit polymerization are promising.
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Abstract
Background: A lp h a-i antitrypsin (A iA T) deficiency is the 
most common genetic cause of liver disease in early child­
hood. Several studies, mostly from transplantation centers, 
have reported a poor outcome of patients with neonatal 
cholestasis due to A iA T  deficiency. We retrospectively 
studied the natural course of liver disease in a cohort of 
patients with neonatal cholestasis due to A iA T  deficiency. 
Methods: We studied neonates who were diagnosed with a 
ZZ or SZ phenotype within the first 3 months of life and who 
had neonatal cholestasis. Patients born in the Netherlands 
between January 1991 and December 2006 were included. 
Clinical and biochemical parameters at presentation were 
recorded. Outcome was reported at end of follow-up and 
in 5- and 10- years follow-up cohorts.
Results: In this 16 years time frame 50 patients were 
identified. A total of 15 neonates presented with vitamin K 
deficiency bleeding. During follow-up 5 (10%) patients 
died and 2 (4%) patients received liver transplantation. At 
the end of follow-up 12% had cirrhosis, 62% had abnormal 
liver enzymes and/or hepato-splenomegaly and 12% had 
no biochemical or clinical abnormalities. Survival without 
liver transplantation was 87% in the 5-years follow-up 
cohort and 73% in the 10-years follow-up cohort. 
Conclusions: In our study, the natural outcome of patients 
with neonatal cholestasis due to A iA T  deficiency is better 
than was suggested in studies originating from transplan­
tation centers, but similar to other cohort studies.
P ro g n o s is  o f  n e o n a ta l c h o le s ta s is  d u e  to  A 1A T d e f ic ie n c y
Background
A iA T deficiency is a hereditary disease characterized by the hepatic production 
of an abnormal A iA T  protein that can not completely be released into the 
plasma. 1This leads to deficiency of serum A iA T and subsequently to an impaired 
protection of the lungs against proteases resulting in pulmonary emphysema; 
the hepatic accumulation of the abnormal protein can lead to liver disease.The 
A iA T  protein isencoded bythe protease inhibitor(Pi) locus located on the long 
arm of chromosome i4q3i-32.3.This locus is highly polymorphic, and so far more 
than 100 different A iA T  isotypes have been identified, which can be detected by 
iso-electrophoresis of the protein or mutational analysis. The most common M 
allele results in a functional normal protein with normal serum A iA T  levels. Two 
frequent variants p.glu342lys (denoted as Z allele) and the p.glu264val (com­
monly referred to asthe S allele) are encountered in Western Europe.2The point 
mutation found in the Z variant destabilizes the loop-sheet polym erization3 
of the A iA T  molecule, resulting in chains of polymers that are retained in the 
liver cells.4 In Pi ZZ homozygous subjects, this results in a severe deficiency of 
serum A iA T  and in accumulation of the abnormal protein in the endoplasmatic 
reticulum of the hepatocytes, which may lead to symptomatic liver disease.5 
The S variant of the A iA T  molecule has less deleterious effect on the protein. 
Consequently liver disease is uncommon, and only seen in SZ patients.6-7 
A iA T  deficiency type Pi ZZ isthe most common genetic cause of liver disease in 
early childhood. Symptomatic patients generally present with neonatal cholesta­
sis, or less commonly later in childhood with hepato- and/or splenomegaly or 
cirrhosis.6-8-9 In Sweden 200,000 neonates were screened for A iA T  deficiency; 
120 patients with Pi ZZ were identified but only 22 of these children presented 
with neonatal cholestasis.10 After 4 years follow-up 4 patients had died (18%);
3 patients due to their liver disease and 1 patient of aplastic anemia. This patient 
had cirrhosis at autopsy.11-13 However in other studies up to 50% of the patients 
with A iA T  deficiency related neonatal cholestasis either died or had to be 
transplanted.14-18 Because these studies were mainly done in transplantation 
centres, they may not be representative forthe natural course of A iA T deficiency 
related neonatal cholestasis.
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Therefore we set out to study the natural course of liver disease due to A iA T  
deficiency in all children presenting with neonatal cholestasis in the Netherlands 
born between January 1991 and December 2006.
Methods
Patients were included when they were born between January i st 1991 
and December 31st 2006 and had presented with neonatal cholestasis due to 
A iA T  deficiency. Patients were identified by searching the databases of the
5 centers in the Netherlands where phenotyping or genotyping for A iA T  
deficiency is routinely performed. Files of all patients, that had genotyping 
and/or phenotyping done within the first three months of life were reviewed 
by contacting the referring physician. Subsequently, a clinical database was 
established that contained the following data: date of birth, sex, age at 
presentation, birth weight, presenting symptoms, AiAT-phenotype, duration 
of follow-up with biochemical markers and clinical outcome.
Results
Patients
A total of 56 children who were diagnosed with a Pi ZZ of Pi SZ phenotype 
were analyzed; 4 children were sibs of known patients and had no evidence of 
neonatal cholestasis; they were excluded from further analysis. Therefore 52 
patients met the criteria for inclusion in this study. Two of these patients, for 
whom clinical and biochemical data at presentation and follow-up were 
unavailable, had to be excluded. Our cohort therefore consists of 50 patients 
(32 boys, 18 girls). Pi ZZ phenotype was found in 49 children; one child had a 
Pi SZ phenotype.
Presentation
The median age at presentation was 5 weeks (range 0-12 weeks). Median birth 
weight was 3205 grams (n=43, range: 1675-4595 grams).The initial prestentation 
within the group of 50 patients, was jaundice in 26 patients, 9 children presented
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initially with failure to thrive, which could subsequently be attributed to 
malabsorption due to cholestasis, while 15 patients presented with clinical 
signs of vitamin K dependent hemorrhagic disease. Intracranial hemorrhage 
w asthe presenting symptom in 7/15 children.19 Base-line patient and laboratory 
characteristics are outlined in table 3.1.
Table 3 .1 : Baseline characteristics in 50  neonates w ith  a lp h a -i antitrypsin deficiency
Total number of patients 50
Male/female 32/18
Median age at presentation in weeks 5 (0-12)
(range)
Median AST (range) 89 (17-2106)
(n<45 IU/1)
Median ALT (range) 54 (14-1490)
(n<45 IU/1)
Median GGT (range) 4 5 7 (80-2526)
(n<45 U /l)
Median total bilirubin (range) 106 (18-490 )
______________________________________ (n<17 fjm o l/ l)_____
Baseline characteristics and biochemical results of 50 patients with neonatal cholestasis due to A1AT deficiency.
Overall outcome
Median follow-up time was 6,1 years (range: 1 month - 1 5  years). In this group of 
50 patients 5 neonates died (10%). Two boys died as a result of decompensated 
liver failure at an age of 26 weeks and 49 weeks respectively. One boy died at 
an age of 26 months after screening for living related transplantation which 
was refused by his parents. Furthermore, 1 boy, born in 2005, died at an age of
6 weeks as a result of massive intracranial hemorrhage. Lastly, 1 girl, born in 
1991, died at an age of 7 months after reconstruction of an atrio-ventricular 
septum defect; she developed extensive cardiac and respiratory complications. 
Given the unrelated cause of death this patient was excluded from further 
outcome analysis. Two girls (4%) underwent orthotopic liver transplantation 
(OLT) at age 1 respectively 7 years. After transplantation these children had no 
evidence for liver disease. At last follow-up six patients had clinical or histo­
logical signs of cirrhosis, but were clinically stable; laboratory data showed 
normal synthetic capacity of the liver. Of the remaining 37 children, 6 patients 
had elevated liver enzymes with hepatomegaly without splenomegaly and
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25 patients had persistent elevated liver enzymes, but no hepato- and/or 
splenomegaly. Lastly, 6 patients had normal liver enzym es and no clinical 
evidence of hepato- and/or splenomegaly.
5-years and 10-years follow-up cohorts
Five-years outcome could be analyzed in 32 children born before 2001. In this 
group3 children died and 1 child underwent livertransplantation; consequently, 
28/32 (87%) survived without liver transplantation. A total of 22 out of these 
28 patients had elevated liver enzymes, of whom 4 had clinical signs of cirrhosis; 
the remaining 6 children had normal liver enzymes. Ten-years outcome could 
be analyzed in 15 children born before 1996. In this group 2 children died and
2 children underwent liver transplantation, thus 11/15 (73%) survived without 
liver transplantation. A total of 6 out of these 11 children patients had elevated 
liver enzymes and 5 children had normal liver function tests. Our data are 
compared with the data as could be retrieved from the Sveger studies.10-12 
(Table 3.2)
Table 3 .2 : Follow-up in neonatal cholestasis due to  a lp h a -i antitrypsin deficiency. Current data
compared w ith  studies from  Sveger *10 12*
Normal liver Elevated ALT Cirrhosis OLT or death
enzymes
Sveger 4- year fo llo w -up 4/16* (25%) 12/16* (75%) 2/18(11% ) 4/22(18% )
Present study 5-year follow-up 6/28 (21%) 22/28 (79%) 4/28  (14%) 4/32  (13%)
Sveger 8- year fo llo w -up 4/11* (37%) 7/11* (63%) 0/11 (0%) 6/21(29%)
Present study 10-year follow-up 5/11  (45%) 6/11 (55%) 0/11 (0%) 4/15  (27%)
*  Irrespective of the presence of cirrhosis; ALT is considered elevated when > 45 I U/l. 
+ assessment of liver enzymes not performed in all patients
Discussion
Several studies have reported the outcome of liver disease in children 
with A iA T  deficiency. Most of these studies were done in transplantation 
centers, suggesting that up to 50% of this group has to be transplanted, with 
a substantial proportion of cirrhosis in the rem ainder.15-18
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Based on ourclinical experience in children with symptomatic A iA T  deficiency, 
we had the impression that the majority of patients have a better prognosis. 
As neonatal cholestasis is by far the most common presentation of A iA T  
deficiency we set out to identify all children with this presenting symptom and 
born in the Netherlands from 1991-2006. Survival without livertransplantation 
was 87% in the 5-years follow-up cohort and 73% in the 10-years follow-up 
cohort.The studies initiated by Sveger more than 30 years ago, showed a similar 
outcome. (Table 3.2) The data of these two studies, both without obvious 
selection bias, are in contrast with data from transplantation centers which 
generally show a worse prognosis.15-18 An overview of these studies and a 
summary of our overall results is given. (Table3-3)
Table 3.3: Prognosis of neonatal cholestasis due to A iA T  deficiency. Results of several 
studies coming from transplantation centers 1^5 l8  ^and an overview of the results of our 
present study
Psacharopolous
(1983)
G rishan
(1988)
Ibarguen
(1990)
Francavill 
a (2000)
Present 
study (2009)
N um ber of patients 67 15 851 82 5°
M e d ia n fo llo w -up  (years) 17 3,7 4,8 10 6,1
Death or transplantation (%) 19 (28%) 5 (33%) 43 (51%) 21 (26%) 7 (14%)
Cirrhosis (%) 19 (28%) 3 (20% ) 7 (8%) 6 (7%) 6 (12%)
Elevated liver enzym es and/or 14 (21%) 7 (47%) 20 (24%) 30 (37%) 31 (62%)
hepato-/splenom egaly (%) 
N orm al liver functio n (%) 15 (22%) 0 (0%) 15 (18%) 25 (30%) 6 (12%)
1 Number of children presenting with liver disease due to AIAT deficiency; 50 children presented with neonatal 
cholestasis; the others presented later in childhood.
In our cohort 15 patients presented with clinical signs of vitamin K deficiency, 
with 7 having an intracranial hem orrhage19. Although it is well known that 
neonatal cholestasis due to A iA T  deficiency is a risk factor for hemorrhagic 
disease of the newborn6-19, it was thought that this problem could be effec­
tively prevented when giving vitamin K supplements to breastfed infants20. 
However recent evidence suggests that the daily oral vitamin K prophylaxis 
for breast fed children, as recommended inthe Netherlands, hasa sub-optimal 
efficacy, especially in patients with cholestasis.21-22 Therefore this vitamin K 
prophylaxis schedule is now being revised. Only a minority of patients with
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A iA T  deficiency presents with neonatal cholestasis. Similarly, within this 
group, only a subgroup will progress to severe liver disease. It is tempting to 
speculate that, apart from environmental factors, modifier genes might be 
responsible for this difference. In fact a recent study showed an association 
between a functional SNP in the A iA T  gene and liver disease.23 
We conclude that the majority of patients presenting with neonatal cholestasis 
due to A iA T  deficiency remains symptom free or only has elevated serum 
transaminases. Nevertheless, a significant proportion of patients develops 
cirrhosis, sometimes with end-stage liverdisease; inthese patients livertrans- 
plantation may be necessary.
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Abstract
Objective: Exclusively breast-fed infants with unrecognized 
cholestatic jaundice are at high risk of a vitamin K deficiency 
(VKD) bleeding. It is presently unknown whether this risk 
depends on the degree of cholestasis. Since alpha-i-anti- 
trypsin deficiency (A iA T  deficiency) induces a variable 
degree of cholestasis, we assessed the risk ofVKD bleeding 
in infants with cholestatic jaundice due to A iA T  deficiency. 
Patients and methods: Infants with a ZZ or SZ phenotype 
born in the Netherlands between January 1991 and 
December 2006 were identified from the databases of the 
5 Dutch diagnostic centres for alpha-i-antitrypsin pheno- 
typing and/or genotyping. We determined the risk ofVKD 
bleeding upon diagnosis of A 1 AT deficiency in breastfed 
and formula-fed infants and searched for correlations 
between serum levels of conjugated bilirubin and the risk 
of bleeding.Results: A total of 40 infants with A iA TD  were 
studied. VKD bleeding was noted in 15/20 (75%) of breast­
fed infants, compared with 0/20 of formula-fed infants 
with A iA T  deficiency. The relative risk for VKD bleeding in 
breast-fed versus formula-fed infants was at least 15.8 
(95% confidence interval 2.3 to 108). Conjugated bilirubin 
levels at diagnosis did not correlate with the risk ofV K D  
bleeding.
Conclusions:The risk ofVKD bleeding in breast-fed infants 
with A iA T  deficiency was high and did not correlate with 
serum level of conjugated bilirubin at diagnosis. A similar 
absolute risk was previously reported in breast-fed infants 
with biliary atresia under the same prophylactic regimen. 
This confirms that -  without adequate prophylaxis -  the 
risk ofVKD bleeding is uniformly high in exclusively breast­
fed infants with cholestatic jaundice.
Bleeding in in fan ts  w ith  A1AT d e fic iency
Introduction
Vitamin K prophylaxis aims to protect infants against the potentially life 
threatening coagulation disorder that results from severe vitamin K deficiency 
(VKD). In breastfed infants VKD bleeding may occur within days of birth dueto 
the low vitamin K stores at birth1, the short half life of vitamin K2-3 and the low 
vitamin K content of human milk4. An adequate dose of vitamin K given orally or 
by injection at birth effectively prevents VKD bleeding in the first week of life. 
However, ongoing vitamin K supplementation is necessary to prevent VKD bleed­
ing after the first week of life (late VKD bleeding) in breastfed babies having oral 
prophylaxis. Even with these regimens some infants do develop late VKD bleed­
ing, usual ly due to unrecognized cholestasis causing vita mi n K m alabsorption.5-8 
As late VKD bleeding is associated with intracranial haem orrhage (ICH) 
-  resulting in significant mortality and long term m o rb id ity- in approximately 
50% of cases,9-11 it is especially important to prevent this complication. We 
recently reported that -  despite routine vitamin K supplementation - t h e  risk 
ofVKD bleeding in Dutch breastfed infants with biliary atresia (BA) is approxi­
mately 80 percent. VKD bleeding has also been described in infants with various 
etiologies of neonatal cholestasis,5-8 but it is unknown w hetherthe risk ofVKD 
bleeding in these diseases is equally high. In these other causes of cholestasis 
(and contrary to BA) obstruction of bile flow is generally incomplete, allowing 
some bile to enter the duodenal lumen. Partial obstruction of bile flow is associ­
ated with lower degrees of conjugated bilirubin.12Theoretically, residual bile flow 
could aid vitamin K absorption, and reduce the risk ofVKD  bleeding. A lpha-i- 
antitrypsin (AiAT) deficiency -  the next most frequent cause of cholestatic 
jaundice in infancy after BA -  is associated with varying degrees of liver 
involvem ent.13-14 Cholestatic jaundice is present in only approxim ately 1 in 10 
infants with a ZZ phenotype13 and is even less frequent in patients with an SZ 
phenotype. Moreover, the degree of cholestasis in symptomatic infants can vary 
from mild to severe.13Thus, A iA T  deficiency induced cholestatic liver disease 
represents an attractive model to study the influence of varying degrees of 
cholestasis on the development ofV K D  bleeding at initial presentation. The 
objectives of this study were 1) to determine the absolute and relative risk ofVKD 
bleeding at initial presentation of cholestaticjaundice induced byA iA T deficiency 
in exclusively breastfed versus formula fed infants and 2) to investigate whether 
varying degrees of jaundice are associated with a different risk of bleeding.
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Methods
Study population
Dutch patients born from January 1991 until December 2006 presenting with 
neonatal cholestasis due to A iA T deficiency were identified from the databases 
of the 5 centres in the Netherlands involved in A iA T genotyping or phenotyping. 
Patients were provisionally included if a ZZ or SZ genotype or phenotype was 
generated within the first 6 months after birth. Subsequently, patient files 
were reviewed at the hospital where the patients originated to obtain relevant 
demographic data and clinical characteristics. The same exclusion criteria 
were used as described previously for BA.11 Briefly, exclusion criteria were: 
1) gestational age less than 37 weeks 2) birth weight below 2000 grams, 
3) absence of cholestasis (with cholestasis defined as a total serum bilirubin 
concentration above 50 |_imol/L, with a conjugated fraction of at least 20 
percent). External Quality Assessment is in place throughout the Netherlands 
fo rth is measurement, 4) a diagnosis of cholestasis before age 8 days. An addi­
tional exclusion criterion was the presence of an older sib with cholestatic 
jaundice due to A iA T  defiiciency, as this should affect the advised prophylactic 
regimen. Infants were categorized as "breast-fed" if they had received exclu­
sively breastfeeding from birth onwards. All other infants were categorized as 
"form ula-fed".
Vitamin K prophylaxis
Since 1990 all infants born in the Netherlands receive an oral dose of 1 mg 
vitamin K directly after birth. Upon breastfeeding, parents are advised to give 
their child a daily oral dose of 25 |_ig vitamin K from the second week of life 
until the end of the 13th week. For daily dosing of vitamin K, a dietary supplement 
is used in which vitamin K is solved in arachid oil. The vitamin K prophylaxis 
can be stopped earlier if breastfeeding accounts for less than fifty percent of the 
daily intake.15 Formula-fed infants only receive vitamin K prophylaxis directly 
after birth.Thereafter, they are expected to receive sufficient amounts of vitamin 
K, since the formula feedings commercially available in the Netherlands contain 
approxim ately 50 |_ig vitamin K per litre.16
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Vitamin K deficiency
We calculated the prothrombin ratio (PR) at initial diagnosis to be able to com ­
pare coagulation parameters from different hospitals, and used it to assess the 
presence ofVKD. In case of a prothrombin time (PT) in seconds the PR was deter­
mined asfollows: PR = PTpatient / PTcontrol. If a PTcontrol was not determined 
by the laboratory, it was defined as the mean of the provided reference range. 
If not available, the International Normalized Ratio (INR) was used as PR. VKD 
was defined as a PR above 1.5 in line with our previous study.11 VKD bleeding 
was defined as bruising, bleeding or ICH in combination with a PR of more 
than 4 in any infant between eight days and six months of age and normalizing 
after administration of vitamin K.9 A diagnosis of ICH was made only if there 
was radiological confirmation. Clinical signs suggesting ICH (high pitched cry, 
irritable, convulsions) but without radiological confirmation were also listed, but 
alone were not taken as diagnostic. Life threatening VKD bleeding was defined 
as either an ICH or isolated respiratory and /or circulatory insufficiency.
Statistical analysis
We performed a student t-test for clinical and biochemical parameters with a 
normal distribution pattern to test for statistical differences between groups. 
Kruskal-Wallis analysis was used for parameters with a non-normal distribution. 
A Chi Square test was performed to determine statistical significance between 
groups in case of dichotomous parameters. The relative risks and 95% confi­
dence intervals (Cl) for VKD bleeding and biochem ical levels o fV K D  were 
calculated. Since computation of a RR requires at least one positive case in 
each quadrant a dummy case was added if necessary to be able to compute a 
(minimal) relative risk. Approval for the study was obtained from the University 
Medical Center Utrecht ethics committee.
Results
Between January 1991 and December 2006, 56 patients with A iA T  deficiency 
were added to the Dutch A iA T  deficiency registry. Fifty-five infants were ZZ, 
one was SZ. Sixteen infants did not meet the inclusion criteria for this study,
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as described in detail in table 4.1. Twenty (50%) of the remaining 40 infants 
were exclusively breast-fed. Infants were categorized according to the type of 
prophylaxis they received. Table 4.2 summarizes the clinical characteristics of 
breast-fed infants on daily oral prophylaxis and of formula-fed infants.
Table 4.1: Patients and population
Live births 3,530,583
No. of documented cases 56
Incidence of documented cases 1.6/100,000
Excluded
Positive family history, no cholestasis 5
Positive family history, cholestasis 2
Gestational age<37 weeks 3
Diagnosed prior to 1st week 4
Unknown feeding type 2
Included 40
Breast-fed 20
Formula- fed 20
*derived from the central bureau o f statistics (http://statline.cbs.nl)
Table 4.2: Patient characteristics
Total Breast-fed +25ug vitamin K 
daily oral n=20
Formula-fed
n=20
P-value
Male sex-no. {%)* 28 (70) 16 (80) 12 (60) 0.30
Birthweight-g* 32851548 3388±523 3193±554 0.27
Age at diagnosis-days§ 35 (28^ 7) 31 (27-42) 39 (30-60) 0.10
Weight at diagnosis-g* 3907±660 4134±736 3660±483 0.09
Bilirubin total-umol/l* 107±41 104±34 177±55 0.36
Bilirubin direct-umol/l* 69±32 63±25 74±38 0.35
ASAT-U/I§ 98 (78-141) 95 (83-138) 100 (82-141) 0.70
ALAT-U/I§ 57 (39-83) 56 (31-72) 61 (43-108) 0.22
GGT-U/I 556 (315-874) 567 (230-875) 584 (335-918) 0.81
* Plus-minus values are means ±SD. p value was determined with independent sample t-test. § Values are median 
(interquartile range), p value was determined with Mann Whitney U. *P-value was determined with Fisher Exact.
Vitamin K deficiency in AiATdeficient infants at initial presentation
VKD was evident in 16 of 20(80%) exclusively breast-fed infants with A iA T  
deficiency and was associated with VKD bleeding in 15/20 (75% ).(table 4.3) 
The PR in patients presenting with VKD bleeding was above the upper limit of 
quantification in 13/15 cases.(table 4.4) Life threatening consequences were 
found in 8/20(40%) infants. One infant presented with respiratory insufficiency
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without documented ICH. In seven infants an ICH was documented and one of 
these infants died as a consequence. Additionally, two infants had symptoms 
suggestive of an ICH (convulsions in 1, irritability in 1), without radiological 
confirmation.
Table 4.3 : Risk of vitamin K deficiency in breast-fed and formula-fed infants with alpha-1
antitrypsin deficiency.
Breastfed +25ug vit 
K daily oral
Formula
fed
P-
value
Breastfed +25ug vit K daily oral 
vs formula fed
RR (95%CI)
Vitamin K deficiency* 
Vitamin K deficiency 
bleeding 
Intracranial 
haemorrhage
16/20 (80%) 
15/20 (75%)
7/20 (35%)
1/20 (5%) 
0/20 (%)
0/20 (0%)
<0.001
<0.001
0.008
16.0
15.8*
7.4*
(2.3-109)
(2.3-108)*
(1.0-54.5)*
Data are number/total number (%). The p value was determined w ith Fisher exact, ^defined by PR>1.5 for VKD and PR>4.0 
fo r severe VKD and normal thrombocyte count. *  a positive dummy was added in the formula group to  compute a 
(minimal) RR.
The risk of (severe) VKD was significantly lower in infants receiving formula 
feeding (p<o.ooi). None of the infants receiving formula presented with a 
VKD bleeding, and only one had a (mild) VKD. The minimal relative risk for 
VKD bleeding in breast-fed versus formula-fed infants was 15.8 (95% Cl 2.3- 
108).This calculation was performed after adding a positive dummy, based on 
the assumption that the next included patient would have received formula 
and presented with a VKD bleeding. Breast-fed infants presented earlier than 
formula-fed infants, although this was not statistically significant (table 4.2) 
This is in line with our previous study of BA infants.11 This indicates that the 
high rate ofVKD bleeding in breast-fed infants with A iA T  defidnecy accelerated 
recognition of cholestasis, and argues against delayed recognition as a cause 
for the higher risk of bleeding.
Cholestatic jaundice and the risk ofVitam in K deficiency bleeding
Mean total and conjugated bilirubin levels in the group of 20 breast-fed 
infants, as shown in table 4.2, were 104 (± 34) |_imol/L and 63 (± 25) |_imol/L, 
respectively and did not correlate with the risk of VKD or VKD bleeding.
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Instead, total bilirubin levels in breast-fed infants presenting with an ICH (n=7) 
were significantly lower than in infants without ICH (n=i3), (80 vs 116 |_imol/l, 
p  =  0 . 0 2 ) .
Table 4.4 Infants with A iA T  deficiency presenting with biochemical vitam in K deficiency.
gender Age
(days)
bilirubin
(conju-
gated/
total)
PR APTT
(sec)
Normalisation 
after vit. K 
(PR if 
available)
ICH other
bleeding sites
Neurological
outcome
M 29 52/96 6.2 86 1.1 + - normal up to 
l y r
V 41 56/73 >10 >240 1.4 + - epilepsy
M 35 86/106 >10 >300 1.0 + melena,
hematemesis
epilepsy and 
PMR
M 20 54/79 >10 >100 + + umbilical,
melena
aggression, 
development 
al delay
M 31 45/81 >10 >100 0.9 + bleeding after
vena
puncture
coma, died
M 21 52/70 >10 >240 0.9 + bleeding after
vena
puncture
pyramidal 
tract signs, 
normal 
development
V 37 30/54 >10 173 1.5 + - hemianopsia
M 28 69/112 >10 >240 1.1 +/- irritable hematomas normal
M 37 90/100 >10 >200 + ±r
convulsion
hematemesis,
hematomas
normal
M 27 30/59 >10 >150 1.1 bleeding after
vena
puncture
normal
M 13 36/84 6.4 170 1.5 - umbilical normal
M 47 31/110 >10 >150 1.1 - bleeding after 
vena
puncture$
normal
M 47 132/174 >10 181 1.3 oozing 
scratchmark 
on hand
normal
M 42 85/141 >10 >180 1.0 - hemotomas,
hematemesis
normal
M
V
v  *
50
28
35
61/127
75/80
70/96
>10
4.8
1.8
171
132
49
+
1.0
#
hematomas normal
* Formula fed; # isolated reduction of vitamin K dependent coagulation factors;$ respiratory insufficiency.
52
Bleeding in in fan ts  w ith  A1AT d e fic iency
Discussion
The results of this study indicate that exclusively breast-fed infants with A iA T  
deficiency have a high risk of developing a VKD bleeding before recognition of 
cholestatic jaundice underthe present Dutch vitamin K prophylaxis. Of breast­
fed infants, 75% presented with a VKD bleeding and 35% presented with an 
ICH. No VKD bleeding was documented in (partially) formula-fed infants. 
These findings extend our previous observations in infants with BA11 to a 
disease entity with a milder and more variable degree of conjugated hyper­
bilirubinemia. To our knowledge this is the first nation-wide study examining 
the risk of VKD bleeding in infants with A iA T  deficiency. Based on the premise 
that A iA T  phenotyping is a regular part ofthe workup of cholestatic jaundice 
in infancy we investigated the databases from the diagnostic centers performing 
A iA T  phenotyping in the Netherlands. Out of a birth cohort of 3,138,576 infants 
55 cases of Pi ZZ (and one with Pi SZ) were identified. Fifty ofthe Pi ZZ infants 
had documented cholestatic jaundice, amounting to an incidence of 1.6/100,000. 
This incidence is very similar to the expected incidence of 1.3/100,000, which 
is based on the estimated incidence of Pi ZZ in the Netherlands (i:g 5 36 )17 and 
the previously documented risk of developing cholestatic jaundice in infancy 
in case of Pi ZZ phenotype of i2 % 13.
Since we aimed to estimate the risk of late VKD bleeding under the current 
Dutch prophylaxis we carefully excluded infants who may have received addi­
tional vitamin K, such as premature infants. Another source of misclassification 
may originate from the assumption that all breast-fed infants indeed received 
the prophylaxis according to national guidelines, unless otherwise stated in 
patient files. However, data from other European countries indicate that adher­
ence to a prophylactic regimen executed by parents is approximately 85%.8'18'19 
In the group of breast-fed infants with A iA T  deficiency, total and conjugated 
bilirubin levels (104/63 |_imol/L) were significantly lowerthan those in breast-fed 
babies with BA in the Netherlands (147/98 |_imol/L, p <o .ooi).n  Nevertheless, 
the risk of developing VKD bleeding was similar in the two groups (75 and 83%, 
respectively, p=o.4g), as was the age at presentation (35 and 36 days, respec­
tively). No association was found in the present study between the degree of 
(conjugated) hyperbilirubinemia and the risk ofVKD  bleeding. These findings
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suggest that infants with cholestatic jaundice are at a similarly high risk 
of VKD bleeding, regardless of its degree. Although counter-intuitive, this 
notion is supported by other lines of evidence. First, VKD bleeding has been 
repeatedly reported in infants with minimal cholestatic jaundice (total bilirubin 
21-62 |_imol/L).20-23 Second, in a Japanese study investigating the incidence of 
subclinical VKD, highly elevated PIVKA-II levels were found in 8/22,000 infants 
at age 4 weeks, all of whom were breast-fed and had moderately elevated 
conjugated bilirubin levels (range 17-45 |-imol/l).24The incidence of cholestatic 
jaundice found in this study was 1/2750, similar to the reported incidence of 
(transitory) cholestasis in infancy25, suggesting that nearly all breast-fed infants 
with some degree of cholestatic jaundice developed coagulation abnormalities. 
It could be argued that infants with underlying cholestatic liver disease 
should be protected against VKD bleeding by early diagnosis and appropriate 
treatment, rather than by routine prophylaxis. Indeed, 2/7 cases of ICH in 
this report could have been prevented if doctors had rightly regarded the 
harmless-looking (warning) bleeds as a medical emergency and reacted with 
prompt parenteral administration of vitamin K. Moreover, all infants with 
A iA T  deficiency that developed VKD bleeding had bilirubin levels that are 
recognisable on physical examination, suggesting that earlier recognition of 
jaundice could help prevent VKD bleeding. However, various attempts aimed 
at increasing awareness and early recognition of cholestatic jaundice by 
parents26 and health professionals27-28 had only a modest effect on the age 
at diagnosis.
It has been recently suggested that the decreasing incidence of VKD bleeding 
in the UK is due to increased awareness of the importance of jaundice beyond 
two weeks of life29, although the effect of this program on the age at presen­
tation of cholestatic jaundice has not (yet) been published. Our data in infants 
with A iA T  deficiency and BA11 indicate that the age at diagnosis would have 
to be reduced by approximately 3 w eeksto prevent all bleedings.Theoretically, 
newborn screening would be an attractive option, but quantification of serum 
bile acids failed to separate infants with cholestatic jaundice from healthy 
infants.30Therefore, underthe present circumstances adequate routine vitamin 
K prophylaxis seems to be the most reliable way to protect all infants with
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unrecognized cholestasis. In previous studies vitamin K prophylaxis was shown 
not only to reduce the risk of VKD bleeding but also to postpone its 
occurrence.5-10-29
Interestingly, the age at presentation in the cohort described here is similar 
to the age reported in infants who received only a single oral dose at birth. 
Therefore, it is doubtful whetherthe daily oral administration of 25 microgram 
vitamin K in the first 3 months of life, as is customary in the Netherlands, had any 
effect at all in infants at the highest risk of VKD bleeding. If oral prophylaxis 
is to be continued in the Netherlands it seems prudent to choose a dose and 
formulation with proven efficacy. However, the formulation which significantly11 
protected cholestatic infants is no longer commercially available. As surveillance 
data indicate that a mixed micellarformulation is equally effective,5-7 we suggest 
using this.
In conclusion, the absolute risk ofVKD bleeding in exclusively breast-fed infants 
with cholestatic jaundice due to A iA T  deficiency is similar to that in infants 
with BA and does not correlate with the degree of conjugated hyperbili­
rubinemia. These findings suggest that infants with cholestatic jaundice, 
regardless of etiology, are at a high risk o fV K D  bleeding under the current 
Dutch regimen of vitamin K prophylaxis and change is needed. Meanwhile, 
doctors should be aware that early recognition of cholestatic jaundice followed 
by prompt treatment with vitamin K can reduce the risk of life threatening 
VKD bleeding in breast-fed infant.
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Abstract
Background: The role of heterozygosity for a lp h a-i anti­
trypsin (AiAT) alleles in patients with chronic hepatitis C 
virus (HCV) is unclear.There is limited evidence to suggest 
that there is an increased prevalence of heterozygous A iA T  
carriers in HCV, but it is unclear how this affects treatment 
success.
Aim: To investigate the (1) prevalence of A iA T  heterozy­
gosity among 2 HCV cohorts and (2) its effect on treatment 
outcome.
Methods: We performed a retrospective cohort study using 
2 different cohorts. Cohort 1 consists of 678 German HCV 
patients, 507 of them were treated for HCV with standard 
therapy. Cohort 2 consists of 370 Dutch HCV patients of 
which 252 HCV patients were part of a clinical trial (treat­
ment with amantadine or placebo, in combination with 
PEG-interferon alfa-2b and ribavirin) while 37 HCV patients 
received standard therapy. We analyzed A iA T  status using 
direct sequencing of the A iA T  gene (cohort 1) or iso-electro 
focusing of serum (cohort 2). In addition we measured 
A iA T  serum levels (cohort 2).
Results: In total we included 1048 HCV patients; 986 (94%) 
were wildtype (Pi MM), while 61 (6%) were heterozygous 
for a mutant A iA T  allele (41 Pi MS, 20 Pi MZ). Mean A iA T 
serum levels (370 patients) were lower in A iA T heterozygous 
patients (1.68 g/l vs. 1.36 g/l), (p<o.o5) compared to wildtypes. 
Sustained viral response (SVR) after treatment was equal 
between the wildtypes and heterozygotes. (54% vs 56%) 
Conclusion: We found a heterozygosity rate of 0.06, in line 
with healthy controls in other studies. Serum A iA T  levels 
from A iA T heterozygous HCV patients are significantly lower 
compared to wild type patients, although they do not dis­
criminate on an individual level. Finally, SVR in A iA T  w ild­
types was not different from SVR in A iA T  heterozygotes.
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Introduction
A iA T  deficiency is a hereditary disease that is characterized by the hepatic 
synthesis of an abnormal A iA T  protein that cannot be released into the plasma 
completely. Accumulation of mutant A iA T  protein in hepatocytes causes tissue 
damage and eventually ensues in liverand pulmonary disease.The A iA T  protein 
is encoded by the protease inhibitor (Pi) locus located on the long arm of 
chrom osom e i4 q 3 i.2 . This locus is highly polymorphic, and so far more 
than 100 different A iA T  isotypes have been identified. They can be detected 
by iso-electrophoresis of the protein or by mutational analysis of the allele.1 
The wild type allele (Pi MM) results in a functionally normal protein with 
normal serum A iA T  levels. In W estern Europe there are 2 frequent variants 
P.G342K (denoted as Z allele) and the P.G264V (commonly referred to as the 
S allele).2 For example, in the general Dutch population the allele frequency 
for these A iA T  variants is estimated to be 0.02 (Z allele) and 0.04 (S allele).3-5 
The Z allele variant results in polymers that are retained in hepatocytes while 
the S variant of the A iA T  molecule has less deleterious effect on the protein.6 
Hom ozygosity for A iA T  deficiency is associated with liver and pulm onary 
disease, but the picture is less clearfor A iA T  heterozygosity.7-11 
Hepatitis C virus (HCV) is mainly transmitted through contact with blood and 
blood products. More than 80% of all HCV-infected patients will develop 
chronic hepatitis, and in 20% this will lead to liver cirrhosis.12 Treatment 
of HCV aims to eliminate the virus and current standard treatm ent regimen 
consist of PEG-interferon and ribavirin.13 Treatment success greatly depends 
on viral characteristics such as HCV genotype, and viral load but also host 
related factors play a role. For example, presence of the ACC IL10 promoter 
diplotype increasesthe likelihood of reaching a sustained viral response (SVR) 
by more than 3-fold.14
If we focus on the role of A iA T  in HCV, studies have merely investigated the 
prevalence of A iA T  heterozygosity in HCV induced liver disease. Studies in 
pre-transplantation HCV patients demonstrated presence of Pi MZ in 10-13% 
of the patients, compared to 2.8% in controls; suggesting that A iA T  hetero­
zygosity influenced the development and/or course of the liver disease in 
HCV.10-11 A case-control study in Egyptian HCV patientsfound a relatively high 
frequency of Pi M S.15 In contrast, other studies failed to conform th is.16-18
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In vitro studies showed that A iA T  plays a central role in inflammation, both as 
a regulator of proteinase activity and as a signaling molecule for the expression 
of pro-inflammatory m olecules.19 Also, A iA T  has a role in viral clearance, as it 
inhibits human im munodeficiency virus type 1 replication.20 We hypothesize 
that A iA T  heterozygosity puts the host at a higher risk for HCV and decreases 
viral elimination after treatment because of the decreased anti-inflam matory 
response. As a consequence, A iA T  genotype status might be associated with 
the infection rate and treatm ent outcome.
Therefore the aim of our study was (1) to investigate the prevalence of A iA T  
heterozygosity in a large cohort of Dutch and German HCV patients and to 
assess (2) its consequence on treatm ent outcome.
Methods and materials
Patients
We selected two different retrospective cohorts of patients. Cohort 1 consists 
of 678 German HCV patients; 507 of them were treated for HCV and completed 
therapy. Cohort 2 consists of 370 Dutch HCV patients; 289 patients of cohort 2 
were treated and completed therapy. Patients were included regardless of 
their degree of liver fibrosis. We did exclude patients with a hepatitis B or HIV 
co-infection. Our study was approved by the ethical committee.
HCV Treatment
Patients from cohort 1 were treated with interferon monotherapy, a com bina­
tion of interferon and ribavirin or with PEG-interferon in combination with 
ribavirin. A total of 252 patients of cohort 2 were part of a nation-wide, double 
blind, placebo-controlled, randomised multicentre study (CIRA-study).21 Pa­
tients were treated with amantadine or placebo, in all cases combined with 
weight-based ribavirin and high-dose interferon induction therapy followed 
by PEG-interferon alfa-2b. The remaining 37 patients (cohort 2) were treated 
with standard combination therapy. Treatment was given for 24-52 weeks de­
pending on genotype. SVR was defined as a negative qualitative HCV RNAtest 
at 1 year after end of treatment.
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Assays
A iA T  status was analyzed in all patients. We performed mutational analysis 
(cohort 1) and iso-electric focusing and nephelometric measurement of A iA T  
serum levels (cohort 2).
Mutational analysis (Cohort 1)
DNA was extracted from peripheral blood leukocytes. Primer sequences 
used for polymerase chain reaction (PCR) were as follows: exon 5 (PiS), 5'- 
GATGAGGGGAAACTACAGCACCTCG-3'and5'-GGGCCTCAGTCCCAACATGG-3' 
and for exon 7 (PiZ), 5'-GCATAAGGCTGTGCTGACCATCGTC-3' and s'-AGGGTTT- 
GTTGAACTCGACCTC-3'. An automated thermal cycler (Biometra, Gottingen, 
Germany) was used. A iA T  heterozygosity was determined using restriction 
fragment length polymorphism (RFLP). Amplification of the desired products 
was confirmed by direct DNA sequencing. DNA sequences were analyzed by 
sequencing both strands.The reaction products were loaded into an ABI 373A 
fluorescence sequencer (Applied Biosystems, Weiterstadt, Germ any).22
Iso-electric focusing (Cohort 2)
Iso-electric focusing was performed in serum by iso-electric focusing (Phast- 
system, GE Healthcare, München, Germany) and subsequent protein silver 
staining. Patterns were compared to MM, MZ, MS, SZ and ZZ controls. MS 
and MZ designated patterns were subsequently validated by an iso-electric 
focusing with an immuno-fixation method in an independent laboratory.23-24
Nephelometric plasma measurement (Cohort 2)
Determination of the serum A iA T  level was performed by nephelometry. The 
A iA T  reagent was used from the Immage Immunochemistry system (Immage 
Beckmann-Coulter, W oerden, The Netherlands), and a calibrator with an 
assigned A iA T  value and a human quality control sample (Biorad, Liquichek, 
Hercules, CA, USA) were used.25
HCV testing
HCV RNA testing was performed qualitatively (Cobas amplicor HCV MonitorTest, 
version 2.0, detection limit 600 lU/ml, Roche Diagnostics) and quantitatively at
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weeks 24, 52 and 104 (Cobas Am plicor HCVtest, version 2.0; detection limit 50 
lU/ml, Roche Diagnostics). Genotyping was performed by sequence analysis 
of the 5' untranslated region of the HCV genome by the Visible Genetics 
TrueGene Hepatitis C Assay.
Statistical Analyses
The HCV characteristics (genotype) of the wild type patients and heterozygous 
patients were analyzed using Pearson chi-squared test and Fisher's exact test 
where appropriate. The difference in age at start of treatm ent was analyzed 
using student t-test. Differences between serum levels of the wild type patients 
(Pi MM) and heterozygous patients (Pi MS, Pi MZ and Pi SZ) were analyzed using 
student t-test. We used Pearson chi-squared test for analysis of the differences 
in SVR between wild types and heterozygous patients and for analysis of the 
degree of fibrosis in wild types and heterozygotes. All statistical analyses were 
performed using GraphPad Prism 4 (Version 4.02, GraphPad Software Inc., 
San Diego, CA, USA). Atwo-sided p-value of < 0.05 was considered statistically 
significant.
Results
Genotyping
Genotyping was performed in all 1048 patients. Due to technical difficulties, 
iso-electro-focussing failed in a single patient, resulting in 1047 complete 
analyzed patients. We found 986 Pi MM (94%), 41 Pi MS (4%) and 20 Pi MZ 
(2%) patients. (Figure 5.1) Genotype results were within the in Hardy-Weinberg 
equilibrium.
Serum levels
A iA T  levels were measured in serum from 370 HCV patients from cohort 2 
drawn before treatm ent. A iA T  serum levels were higher in Pi MM carriers (340 
patients, mean 1.69 g/l, 95%CI 1.66-1.71 g/l) compared to Pi MS carriers (22 
patients, mean 1.43 g/l, 95%CI 1.34-1.53 g/l) or Pi MZ carriers (7 patients, mean
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Figure 5.1: Prevalence of different A iA T  carrier rates in 1047 patients w ith HCV.
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,1.9% Pi SZ 
. 0 . 1%
1.14 g/l, 95%CI 0.80-1.49 g/l) respectively. The differences between the wild 
types and heterozygous patients were statistically significant (p<o.oi); this also 
holds for the differences between the heterozygous Pi M Sand Pi MZ patients 
(p<o.oi). (Figure 5.2) We detected A iA T  serum levels above 1.0 g/l in all hetero­
zygous Pi MS patients and in 5/ 7 (71%) of the heterozygous Pi MZ patients.
Figure 5.2: A iA T  serum levels in 370 HCV patients arranged to the different A iA T  phenotypes.
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Degree of fibrosis
We assessed the stage of fibrosis using the Metavir score in liver biopsies 
obtained from 409 patients.There was no statistically significant difference in 
the degree of fibrosis between wildtypes and heterozygous patients, (table 5.1)
Table 5.1: Degree of fibrosis in the different A i AT groups (n = 409)
Pi MM Pi MZ and Pi MS
Metavir score * n=383(%) n=26 (%)
F0 - F2 269 (70) 19 (73)
F3 -  F4 114 (30) 7 (27)
*Fo = no fibrosis; F i = minimal fibrosis, 
F4 = cirrhosis or advanced fibrosis
F2 = periportal fibrosis; F3 = bridging fibrosis;
HCV characteristics and treatm ent response
A total of 796 patients completed HCV treatm ent. A iA T  carrier status and 
qualitative HCV RNA 1 year after end of treatm ent were not available for 10 
patients (n = i cohort i;n=g  cohort 2). These patients were excluded from fur­
ther analysis; and data from 786 HCV patients remained available for analysis. 
The distribution of the HCV genotypes at baseline did not differ among the 
groups with different A iA T  genotypes. (Table 5.2)
Table 5.2: Distribution of the HCV genotypes and age in the different A iA T  states (11=795)
Pi MM 
n=745 (%)
Pi MZ 
n=17 (%)
Pi MS 
n=32 (%)
Pi SZ 
n = l (%)
p value *
HCV genotype 
1 450 (60,4) 10 (58,8) 20 (62,5) 0(0)
2 56 (7,5) 1 (5,9) 4 (12,5) 0 (0 )
3 170 (22,8) 5 (29,4) 4 (12,5) 0 (0 ) p=0,89
4 34 (4,6) 1 (5,9) 2 (6,3) 0 (0 )
6 1 (0,1) 0(0 ) 0(0 ) 0 (0 )
unknown 34 (0,46) 0(0 ) 2 (6,3) 1 (100)
Mean age (yrs) 46,6 47,9 45,5 59 p=0,93
* Pi MM vs Pi MZ, Pi MS and Pi SZ
66
A1AT h e te ro zyg o s ity  in HCV pa tie n ts
SVR was reached in 395/736 (54%) wild type patients, in 8/17 (47%) A iA T  Pi MZ 
patients and in 20/32 (62%) of A iA T  Pi MS patients. One Pi SZ patients did not 
achieve SVR. These differences were not statistically significant. (Figure 5.3) 
The addition of am antadine to the com bination of interferon and ribavirin in 
patients from cohort 2 did not affect treatm ent response.26
Figure 5.3: HCV treatm ent response in 736 A iA T  w ildtype (Pi MM) patients, 17 A iA T  heterozygous Pi MZ 
patients, 32 A iA T  heterozygous Pi MS patients and 1 Pi SZ patient.
Pi MM Pi MZ Pi MS 
A1AT Phenotype
Pi SZ
Discussion
This study demonstrates that the efficacy of HCV combination treatm ent with 
(PEG)-interferon and ribavirin is independent of carrier state of AiAT, as 
heterozygous (Pi MZ / Pi MS / Pi SZ) HCV patients had a similar treatment 
response compared to wild type patients (Pi MM). In addition, we did not 
detect an association between A iA T  heterozygosity and the degree of liver 
fibrosis. We found a high rate of SVR in our study population, this can be 
explained by the fact that we included only patients who finished treatment 
with (PEG)-interferon and ribavirin; we did not include patients who stopped 
treatm ent for any reason or who were lost to follow-up.
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There are no previous studies documenting HCV treatm ent response in A iA T  
heterozygosity. Most of the studies in this field have focused on apparent 
differences in A iA T  allele frequency between those with and without a certain 
liver disease.10-11 The common denominator is that a higher prevalence of 
heterozygotes is found in different causes of liver disease; this is particularly 
true for HCV and alcoholic liver disease in pre-transplantation patients.10-11 
We could not confirm the finding of higher A iA T  heterozygosity rates in HCV 
patients, and our data indicate that the A iA T  carrier distribution in HCV 
is in line with the prevalence of control populations in the Netherlands 
and Germany.3-5 Our results are at odds with an Egyptian study that found 
higher prevalence of Pi MS in HCV cirrhotic patients compared with normal 
controls.15 This particular A iA T  allele is rare in Germany and the Netherlands.27 
It is tem pting to speculate why other case control studies in this field 
documented differences in A iA T  carrier rate between patient and controls. 
We surmise that there are 3 possible explanations. First, the variation might 
depend on real population differences. On the other hand, it cannot be 
excluded that bias in selecting controls and patients might have affected 
the results. In addition, the low prevalence of patients with heterozygote 
genotypes might have introduced a type II error giving rise to spurious results. 
Serum A iA T  levels were statistically significantly lower in heterozygous carriers 
compared to A iA T  wild type patients. There was no cut-off point that discrimi­
nated between heterozygotes and wild types. In some laboratories in the 
Netherlands, genotyping is only performed if the serum level is below 1,0 g/l. 
This strategy will miss obvious cases; in our data set, all Pi MS heterozygotes 
and 71% of the Pi MZ heterozygotes. Previous studies also indicated the 
variability of A iA T  serum levels in heterozygous carriers.28-29 Some case 
reports document A iA T  heterozygotes with concomitant HCV30 or alcoholic 
liver disease31 who had consistent normal A iA T  serum levels but A iA T  globules 
in their liver biopsy specimen. It is possible that the liver inflammation is a driver 
for A iA T  production, hence giving rise to 'falsely' elevated A iA T  serum levels. 
Our study was adequately powered to detect differences in treatment outcome 
and to calculate the prevalence of A iA T  heterozygosity in HCV patients in 
the Netherlands and Germany. Nevertheless, our study comes with several
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limitations. The lack of a control population does not allow a firm estimate 
of the allele frequency in relation to the background population.
While A iA T  does not a play a role in the HCV treatm ent response, it is possible 
that there are other important genetic factors. For example, hereditary 
hemochromatosis is a common genetic liver disease that appears to be over­
represented in HCV patients15. Currently, it is not known whether possession 
of the mutant hereditary hemochromatosis allele affects treatment response. 
In conclusion: We found no evidence for an increased prevalence of A iA T  
heterozygosity in HCV patients. Serum A iA T  levels from A iA T  heterozygous 
HCV patients are significantly lower compared to wild type patients, however 
they do not discriminate on an individual level. Finally, we could not confirm 
our hypothesis that HCV patients with A iA T  heterozygosity deficiency had 
worse outcomes on HCV combination therapy.
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Abstract
Backg round: Al p h a-i ant it rypsin(A iA T) deficiency, caused 
by the Z allele (P.E342K) and S allele (P.E264V) in the 
SERPINAi gene, can induce liver and pulmonary disease. 
Different mechanisms appear to be responsible for the 
pathogenesis of these divergent disease expressions. 
The c.-ig73T>C  polymorphism located in the SERPINAi 
promoter region is found more frequent in A iA T  deficiency 
patients with liver disease compared to patients with 
pulm onary disease, but data are lacking regarding con­
tribution to the development of liver diseases caused by 
other etiologies.
A im :T o study the prevalence of c.-igj3T>C, Z allele and S 
allele in a cohort of patients with liver disease of various 
etiologies compared with healthy controls and to evaluate 
its effect on disease progression.
Methods: A total of 297 patients with liver disease from 
various etiologies and 297 age and gender matched healthy 
controls were included.The c.-igj3T>C  polymorphism and 
Z and S alleles of the SERPINAi gene were analyzed by 
real-time PCR.
Results: c.-ig j3T> C  was similarly distributed between 
patients with liver disease of various origins and healthy 
controls. Furthermore, the distribution of c.-ig j3T> C  was 
independent from etiology subgroup. In patients with liver 
disease mean ages at of onset of liver disease were 
44.4, 42.3 and 40.7 years for the c.-1973 T/T, T/C and C/C 
genotype respectively (NS). S allele heterozygosity was 
increased in patients with drug induced liver injury (DILI). 
(OR 4.3; 95%CI 1.1-17.2)
Conclusion: In our study, c.-ig j3T> C  polymorphism was 
not a risk factor for liver disease of various etiologies. In 
addition, S allele heterozygosity might contribute to the 
development of DILI.
Po lym orph ism s o f SERPINA1 gene in ch ron ic  live r disease
Background
A lp h a-i antitrypsin (A iAT) deficiency is a hereditary disease and can induce 
end-organ damage caused by defective A iA T  protein processing. Liver disease 
in A iA T  deficiency is caused by hepatic accumulation of the A iA T  protein and 
pulmonary disease is induced by an impaired protection against neutrophil 
elastase due to decreased serum A iA T .^ T h e  A iA T  protein is encoded by the 
protease inhibitor (Pi) locus located on chromosome i4q32.i(SERP/A /A igene). 
In Western Europe, A iA T  deficiency most commonly results from presence of 
2 genetic variants P.E342K (denoted as Z allele) and the P.E264V (commonly 
referred to as the S allele).3 Liver disease in A iA T  deficiency has a bimodal 
presentation affecting children in neonatal life4 and, less commonly, adults in 
late middle life.5
It is unclear why A iA T  deficiency leads to liver disease in some patients and 
lung disease in others. It appears that environm ental factors are in part 
responsible for this difference. Pulmonary disease develops preferably in 
homozygous Pi ZZ persons who are tobacco smokers or are exposed to airway 
irritants.6 Indeed, smoking is an established risk factor for lung disease as 
A iA T  deficient smokers will develop emphysema at considerable younger 
age, while non-smokers are at risk for liver disease developing later in life.7 
Some 32-37% of A iA T  deficient non-smoking patients will die as a result of 
A iA T  deficiency induced liver disease.8
Apart from environmental factors there is some evidence that genetic factors 
modify the risk for A iA T  deficiency related end-organ damage. For example, 
72% of siblings of probands with A iA T  deficiency related liver disease suffered 
from liver disease, which was concordant for severity in 29%, while 28% had no 
liver involvement.9This suggests presence of genetic modifiers. Indeed a recent 
study identified a novel single nucleotide polymorphism (SNP) g.i26oj6T>C  
(c.-igj3T>C ; ^8004738) in the promoter region of SERPINAi. It appeared that 
the SNP was enriched (15.5%) in a cohort of A iA T  Pi ZZ homozygotes with liver 
disease relative to those with pulmonary disease (6.5% ).10 
As a result of the above-m entioned observations we hypothesized that 
c.-ig73T>C  polymorphism affects susceptibility fo rthe progression of liver dis­
ease in patients with liver disease of various etiologies. Therefore we investigated
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the association of c.-igyjT>C, P.E342K(Z allele) and p.E26^V(S allele) polymor­
phisms in a cohort of patients with liver disease of various etiologies compared 
with healthy controls and evaluated its consequence on course of disease.
Methods
Patients
We recruited patients with various liver disorders, visiting the outpatient clinic 
of the Department of Gastroenterology and Hepatology of the Radboud 
University Nijmegen Medical Center. In addition, age and gender matched 
persons who were unrelated to our patients served as healthy controls. In the 
patient population, clinical and demographic data including age, sex, age at 
first presentation of liver disease, etiology of liver disease and presence or 
absence of cirrhosis were obtained. The absence of liver disease in ourcontrol 
population was established on the basis of self-reporting and none of the 
patients used any medication. Whole blood samples were stored at -20°C. 
Altogetherthe study population comprised 297 patients with various etiologies 
of liver disease and 297 controls. Clinical and demographic data are given. (Table 
6.1) The study was approved by the local ethical committee. (Medical Ethical 
Committee of the Radboud University Nijmegen Medical Center.)
Table 6.1: Baseline characteristics of patients and controls
Patients
(n=297 )
Controls
(n=297 )
p-value
Male (%) 168 (57) 163 (55) 0.74
Mean oge (range) 51.4 yrs (19-85) 51.5 yrs (20-85) 0.94
Mean oge at onset liver disease (range) 43 yrs (7-82)
Cirrhosis (%) 69 (23)
Cause o f  liver disease (%)
-HCV 129 (43)
-AIH/PBC/PCS 53 (18)
-HBV 50 (17)
-Alcoholic liver disease 21 (7)
-NASH/metabolic 16 (5)
-Cryptogenic 13 (4)
-Drug induced liver injury 11 (4)
-Vascular 4 (1)
HCV= hepatitis C virus, AIH/PSC/PBC= autoimmune hepatitis/ primary biliary cirrhosis/ primary sclerosing cholangitis, 
HBV= hepatitis B virus, NASH= non-alcoholic steato hepatitis
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Laboratory
DNA was isolated from peripheral blood using the High Pure PCR Template 
preparation kit (Roche, Mannheim, Germany). The c.-igj3T>C  (^8004738), 
P.E342K (Z allele; c.i024G >A; ^28929474) and P.E264V (S allele; c.7giA>T; 
rsi758o) polymorphisms of the SERPINAi gene were analyzed by real-time 
polymerase chain reaction (PCR) using a dual-color, allele-specific discrimination 
assay with fluorescent labelled probes on the ¡Cycler iQ Multicolour real-time 
detection system (Bio-Rad Laboratories Inc, Hercules, CA, USA). Primer and 
probe sequences (Sigma, St Louis, MO, USA) used for PCR and real time 
detection are listed in the supplem entary table. All of the genotyping results 
in the control population were in the Hardy-Weinberg equilibrium. Haplotypes 
and diplotypes were determined using the Partition-Ligation-Expectation- 
Maximization (PLEM) 1.0 softw are.11
Statistical analysis
Baseline characteristics, differences in allele frequency, diplotypes and 
haplotypes were analyzed using student t-tests, Pearson chi-squared test 
and Fisher's exact test where appropriate. Odds Ratio's (OR) were calculated 
for the association between the studied polymorphisms and the presence of 
liver disease. In addition we calculated OR's for the association between the 3 
polymorphisms and all different subgroup etiologies. We analyzed differences 
in age at onset of liver disease between the 3 different C.-1973 genotypes 
using ANOVA. All statistical analyses were performed using GraphPad Prism 
Version 4.02 (GraphPad Software Inc., San Diego, CA, USA). A two-sided p-value 
of < 0.05 was considered statistically significant. Post-hoc power calculation 
showed the study being adequate powered (88%) to negate our hypothesis 
that c.-igj3T>C  is associated with liver disease of various etiologies (a= 0.05, 
difference in group proportions 10% (20% and 30%)). Power calculations were 
performed using nQuery Advisor 4.0 software (Statistical Solutions Ltd, Cork, 
Ireland). Linkage disequilibrium (LD) values were performed with Haploview 
4.0 software.
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Results
c .- ig j3 T > C  polymorphism
The c.-igj3T>C  polymorphism distribution in 297 patients with liver disease 
due to various etiologies was in line with 297 healthy controls. ic.-1gy3-.JfT 32%, 
T/C 44% and C/C 24% in patients andT/T30% ,T/C 50% and C/C 20% in controls). 
(Figure 6.1) We found no association of the c.-ig j3T>C  polymorphism with any 
of the distinct liver diseases investigated. Next, we observed that mean age at 
onset of liver disease was non-significantly lower in patients with the c.-1973 
C/C allele, as mean ages of onset of liver disease were 44.4 (T/T), 42.3 (T/C) and 
40.7 (C/C) years. (Figure 6.2) Further, possession of c.-igj3T>C  polymorphism 
had no influence on the presence of cirrhosis.
Figure 6.1: Distribution of the c ,- ig /3 T > C  genotypes in 297 patients with liver disease o f various 
etiologies and 297 controls.
100% 1--------------------------------------------
90% j-------------------------------------------------------------
80% ♦
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Figure 6.2: Age at onset of liver disease in 297 patients arranged to the different c .- ig /3 T > C  
genotypes.
T
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Z (p.£342/0 allele and S (P.E264V) allele heterozygosity
We observed a similar Z allele and S allele heterozygosity rate in patients and 
controls (Z allele: 3.0% and 4.7%; S allele: 6.7% and 8.0%). The distribution of 
Z allele heterozygosity was similar among all liver diseases of various etiologies. 
In contrast, S allele heterozygosity was more frequently present in drug induced 
liver injury (DILI) compared with healthy controls (11 patients, 27% vs 8%; OR 
4.27; 95%CI 1.06-17.15). A total of 8 wildtype patients developed DILI likely due to 
clavulanic acid (n=3), azathioprine, sulfasalazine, pantoprazole, methotrexate 
and quetiapine; addionally, the S allele heterozygotes had DILI caused by an­
aesthetic compounds (isoflurane/nestonal), clavulanic acid and celecoxib. Lastly, 
age at onset of liver disease was independent of Z or S allele heterozygosity as 
mean ages were 48.3 (Z allele), 43.2 (S allele) and 42.4 (wildtypes) years.
Haplotyping / diplotyping
Based on the 3 polymorphisms tested, haplotype and diplotype analysis 
were performed. A total of 11 diplotypes could be distinguished. We could not 
detect differences in diplotypes between patients with liver disease of various 
etiologies and controls. Only the CTG haplotype was more frequent found in 
patients with DILI, according to the above-described association between S 
allele heterozygosity and DILI. (Table 6.2) Finally, linkage disequilibrium (LD) 
between the 3 SERPINAi alleles was absent. This was true for patients as well 
as controls. (Figure 6.3)
Table 6.2: Diplotypes in patients with liver disease of various etiology and healthy controls
Diplotype Controls (%) 
n=297
Patients (%) 
n=297
CAG/TAG 130 (43.8) 112(37.7)
TAG/TAG 78 (26.3) 93 (31.3)
CAG/CAG 51 (17.2) 63 (21.2)
CTG/TAG 11 (3.7) 12 (4.0)
CAG/CTG 8 (2.7) 7 (2.4)
TAG/TAA 8 (2.7) 2 (0.7)
CAG/TAA 5 (1.7) 6 (2.0)
TAG/TTG 4 (1.3) 1 (0.3)
CTG/TAA 1 (0.3)
CTG/CTG 1 (0.3)
CAG/CAA 1 (0.3)
Order of alleles : c.-1973T>C- c.791A>T - c.1024G>A/ c.-1973T>C- c.791A>T - c.1024G>A (mutations in bold)
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Figure 6.3: Linkage disequilibrium  (LD) plot across the S ER P IN A i gene.
Patients Controls
The box at the top indicates the S ERP IN A i gene with the 3 investigated SNP's (i=p.£342/C, 2= P.E264.V 
and 3= c .-ig /3 T > C ).  The LD plot is based on the measurement of R2 (values x  0.01). Each diamond 
indicates the pair w ise magnitude of LD. (LD: linkage disequilibrium  is the non-random association of 
alleles at two or more loci. LD describes a situation in which some com binations of a lleles o r genetic 
markers occur more or less frequently in a population than would be expected from a random formation 
of haplotypes from alleles based on their frequencies.)
Discussion
We show that the distribution of SERPINAi c.-igj3T>C  in patients with liver 
disease from various etiologies is similar compared to healthy controls. The 
genotype frequencies in the patient and control groups were in line with those 
from the HapMap database (T/T 30%, T/C 45% and C/C 25%)12. Moreover, we 
found that the distribution of c.-ig j3T>C  is independent from etiology of the 
liverdisease. We also examined whetherthe c.-igj3T>C  polymorphism affected 
age at onset of liver disease. We found a non-significant lower age at onset in 
patients with the C.-1973 C/C genotype compared to other C.-1973 genotypes. 
In addition, we could not demonstrate an association of c.-igj3T>C  on severity 
of liver disease, e.g. cirrhosis. We also investigated other SERPINAi variants and
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found that there was no increased prevalence of Z and S alleles in patients with 
liver disease of various etiologies compared with healthy controls, even though 
we observed an enrichment of S allele heterozygosity in patients with DILI. 
Other investigators have studied the presence of c.-igj3T>C  and A iA T deficiency 
and chronic obstructive pulmonary disease (COPD). Chappell et al. reported an 
enrichment of c.-igyjT>C \n homozygous Pi ZZ neonates with hepatitis (15.5%) 
compared to homozygous Pi ZZ controls (adults with COPD and unaffected 
subjects) (6.5% ).10 Since our study population consisted for a large extent of 
patients and controls with the Pi MM genotype (wildtypes) and hardly any 
subjects with Z and S allele heterozygosity, we cannot compare our data with 
the results of the above mentioned study. Another study showed a decreased 
prevalence of c.-igyjT>C  \n patients with COPD (48.7%) compared to controls 
(52.2%), suggesting a protective effect against COPD.13 It might be possible 
that c.-ig73T>C influences the genesis of liver disease in childhood, in line with a 
recently published report implicating that a variant of the endoplasmic reticulum 
mannosidase I (ERManl) gene is associated with an early onset of end-stage 
liver disease in patients with homozygous (Pi ZZ) A iA T  deficiency.14 
Our data were in contrast with other reports as Z and S allele heterozygosity 
were previously associated with (end-stage) liver disease due to HCV, alcoholic 
liver disease and cryptogenic cirrhosis15-19 and not with DILI. We found a higher 
frequency of S allele heterozygosity in DILI patients. Indeed, experimental 
evidence supports a relation between A iA T  deficiency and DILI as adm inistra­
tion of indomethacin in a homozygous Pi ZZ mouse model leads to increased 
hepatic injury20 and a case report described prochlorperazine induced liver 
injury in a homozygous (Pi ZZ) A iA T  deficient patient21.
We could not demonstrate an association between c.-igj3T>C  and the presence 
of cirrhosis. There have been several genetic case control studies that have 
attempted to detect associations between genetic variations and liver 
fibrosis. For example, the combination of angiotensinogen (ATG) gene variant 
c.1-44 and transforming growth factor beta (TGF|3i )  P.R25P is associated with 
advanced hepatic fibrosis in obese patients with non alcoholic fatty liver 
disease22 but not in patients with other chronic liver diseases.23 Lastly, matrix 
metalloproteinase (M M P)-7(Asp-i37) confers risk of liver cirrhosis.24
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Our study comes with limitations. Our cohort could have suffered from selection 
bias due to patient recruitment in a tertiary referral centre.The strength of our 
study is the sufficiently power to negate a 10% difference in prevalence of the 
c.-ig73T>C  polymorphism between groups. However, the study lacks power 
to demonstrate smaller differences and to perform a thorough subgroup 
analysis. Further research regarding c.-ig j3T>C  should include homozygous 
Pi ZZ adults with liver disease to evaluate whether c.-igj3T>C  is a risk factor 
for a hepatic expression of A iA T  deficiency.
In conclusion: We demonstrated that, in our study, c.-ig j3T>C  polymorphism 
was not associated with liver disease of various etiologies. In addition, S allele 
heterozygosity might be a risk factor for the genesis of DILI.
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Supplem entary: Overview of primers and probes used for real time PCR reactions
Z allele 
(p.E342K)
Forward primer 
Reverse primer 
Probe wildtype 
Probe mutation
AAAACATGGCCCCAGCAG
AG CCTTACAAGTGTCTCTG
Fam-T CAGT CCCTTT CT CGT CG ATGGTCAG-B HQ1
Hex-TCAGTCCCTTTCTTGTCGATGGTCAG-BHQl
S allele 
(p. E26 4 V)
Forward primer 
Reverse primer 
Probe wildtype
Probe mutation
AACATGGCTAAGAGGTGTGG 
ATCTTCTTCCTG CCTG ATG AG 
Fam-CTACAGCACCTGGAAAATGAACTCACCC- 
BHQ1
Hex-CTACAGCACCTGGTAAATGAACTCACCC-
BHQ1
c.-1973 T>C Forward primer 
Reverse primer 
Probe C 
Probe T
AGGCTGGCAGGAGGTTGC 
G AG CTG A ACC AAG AAG G AG G AG 
Fam-TGGCAGCAGCAGCGGCTAGGCC-BHQl 
Hex-TG G C AG C AG C AG C AG CTAG G CC- B H Q1
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Abstract
Background: A lp ha-i antitrypsin(AiAT) deficiency is a com­
mon disorder and leads to pulmonary and/or liver disease. 
Some authors indicate that testing for A iA T  deficiency 
should start with quantification of the serum level, followed 
by iso-electrofocussing and/or polymerase chain reaction 
( PCR) for the Z and S alleles if serum levels are below a cut­
off point of 100 mg/dL.
We wondered w hetherthis diagnostic approach is suitable 
for the detection of A iA T deficiency in chronic liver disease. 
Patients and methods: We studied A iA T  serum levels in 3 
sets of Pi MZ persons. First, 12 Pi MZ patients with liver 
disease due to various etiologies, second a cohort of 6 Pi 
MZ patients with end-stage liver cirrhosis caused by A iA T  
deficiency and lastly 15 Pi MZ controls.
Results: Mean serum levels were 106 mg/dL in patients 
with liver disease of various etiology, 146 mg/dL in patients 
with cirrhosis and 86 mg/dL in controls; p<o.oi. A iA T  serum 
levels were above the suggested threshold of 100 mg/dL in 
50%, 83% and 6.7% respectively.
Conclusion: We showed that A iA T  serum level quantifica­
tion is not suitable for the detection of Pi MZ heterozygosity 
in patients with liver disease. We might have missed Pi MZ 
heterozygosity in the majority of our patients if genotyping 
only was performed when the A iA T  serum level was below 
100 mg/dL. Starting the diagnostic path with quantification 
of the A iA T  serum level runs the risk of missing subjects 
with A iA T  deficiency related liver disease. To prevent 
underdiagnosis, we propose using iso- electrofocussing 
or PCR ratherthan quantification of serum levels.
D ifficu ltie s  in d e te c tio n  o f heterozygous A IA T  d e fic iency
Background
A lp h a-i antitrypsin (A iA T) deficiency is common and affecting 3.4 million 
subjects worldwide and leads to pulmonary and/or liver disease. Most A iA T  
deficient patients are Pi ZZ, Pi MZ or Pi SZ genotype carriers, and A iA T  
deficiency is frequently not recognized.1 Some authors indicate that testing 
for A iA T  deficiency should start with quantification of the serum level, 
followed by iso-electrofocussing and/or polymerase chain reaction (PCR) for 
the most common deficient alleles (Z and S) if serum levels are below a cut-off 
point of 100 mg/dL2-3.
We wondered whether the diagnostic approach starting with serum level 
quantification is suitable for the detection of A iA T  deficiency in chronic liver 
disease.
Methods
We studied A iA T  serum levels in 3 sets of Pi MZ persons. First, 12 Pi MZ 
patients with liver disease due to various etiologies (8 HCV, 2 alcoholic liver 
disease, 1 AIH and 1 PSC), second a cohort of 6 Pi MZ patients with end-stage 
liver cirrhosis caused by histological proven A iA T  deficiency and lastly Pi MZ 
controls (11 unaffected Pi MZ sibs of known patients and 4 Pi MZ controls 
found through a genetic association study). Median ages were 56, 52 and 46 
years respectively (p=o.o5) and gender distribution was similar in the 3 groups 
(male: 56%, 83% and 53% respectively). A iA T  serum levels were performed 
using routine nephelometry, whereas A iA T  carrier state was determined by 
iso-electrofocussing or PCR.
Results
Mean serum levels were 106 mg/dL in patients with liver disease of various 
etiology, 146 mg/dL in patients with A iA T  deficiency related cirrhosis and 
86 mg/dL in controls; p<o.oi. (Figure 7.1) A iA T  serum levels were above the 
suggested threshold of 100 mg/dL in 6 out of 12 (50%) patients with liver
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disease of various etiologies and in 5 out of 6 (83%) patients with A iA T  
deficiency induced cirrhosis. In contrast, in healthy Pi MZ carriers we measured 
an A iA T  serum level above 100 mg/dl_ in only 1 out of 15 (6.7%).
Figure 7.1: A lp h a -i antitrypsin (A iA T ) serum levels of 15 Pi MZ controls, 12 Pi MZ patients w ith liver 
disease of various etiologies and 6 Pi MZ patients w ith A iA T  related cirrhosis.
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In order to exclude that A iA T  levels were falsely elevated due to a general 
acute phase response we measured C-reactive protein (CRP) levels in a subset 
of 11 subjects (3 controls, 5 patients with various liver disease and 3 cirrhotic 
patients). We failed to detect a correlation between A iA T  levels and CRP. 
(r2= 0.13, p=o.28). This suggests that the acute phase response is not the 
major driver of the A iA T  levels in our study population.
Discussion
We might have missed Pi MZ heterozygosity in the majority of our patients 
if genotyping only was performed when the A iA T  serum level was below or 
sim ilar to the cut-off point of 100 mg/dl_. Our finding is corroborated by a 
report of a normal A iA T  serum level in a Pi MZ heterozygous patient with 
A iA T  containing globules in liver biopsy specimen and concomitant HCV4. 
In addition, in 11 out of 20 (55%) patients with end stage liver disease due 
to A iA T  deficiency (Pi MZ and Pi ZZ), A iA T  serum level quantification prior to
90
D ifficu ltie s  in d e te c tio n  o f he terozygous A1AT d e fic iency
liver transplantation was above the suggested cut-off point of 100 mg/dL.5 
This suggests mere serum quantification will miss the significant number of 
patients with bonafide A iA T  deficiency related liver disease. Lastly, another 
study reported the results of 512 samples referred for A iA T  phenotyping. 
These sam ples were analyzed by quantification of the serum level, iso- 
electrofocussing and PCR. In 2% of the samples, results from the 3 tests 
were discordant, frequently due to presence of'norm al' serum levels.6 
We can speculate about the pathophysiologic mechanism of the normal 
serum levels in Pi MZ heterozygotes with liver disease. As A iA T  is an acute 
phase protein and its production and secretion increases with inflammation7-8 
serum levels might be "falsely elevated" and are not reflecting the genotype. 
This is confirmed by a recent study which found that Pi MZ individuals with a 
CRP level >o .8 m g /d Lhad higher A iA T  concentrations than Pi MZ individuals 
with low erCRP levels.9 It is possible that the absence of a correlation between 
CRP and A iA T  serum levels in our population can be explained by the hepatic 
origin of CRP. Our dataset does not allow a firm conclusion in either direction.
Conclusion
We showed that A iA T  serum level quantification is not suitable for the detection 
of Pi MZ heterozygosity in patients with liver disease. Starting the diagnostic 
path with quantification of the A iA T  serum level runs the risk of missing 
subjects with A iA T  deficiency related liver disease. To prevent underdiagnosis, 
we propose starting the diagnostic route with iso- electrofocussing or PCR 
(dependent on the local expertise) ratherthan quantification of serum levels.
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Abstract
Background: A lp h a-i antitrypsin (A iA T) deficiency is a 
genetic disorder that can result in lung and liver injury. 
Both homozygous (Pi ZZ) and heterozygous (Pi MZ and Pi 
SZ) disease appear to cause liver disease, however it is 
unknown whether heterozygous disease induces end stage 
liver disease and hepatocellular carcinoma (HCC). Liver 
transplantation (LT) is the only curative approach at this 
stage of liver disease.
Aim: To study (1) A iA T  deficiency characteristics with 
respect to serum level, phenotype and concomitant liver 
disease (particularly HCC) and (2) patient and graft survival 
in LT for A iA T  deficiency.
Methods: We studied 2 LT cohorts: First, LT recipients with 
A iA T  deficiency in the Netherlands and second, a replicative 
cohort with data from A iA T  deficiency patients collected 
in the European LiverTransplantation Registry (ELTR). 
Results: We analyzed the medical records of 24 adult and 8 
pediatric LT recipients from the Netherlands. HCC was found 
in 7/24 (29%) adult LT recipients; the time between i st pre­
sentation of liver disease and LT was longer in patients with 
HCC. (p<o.oi).The majority of HCC (4/7) was not recognized 
prior to LT. HCC was absent in the pediatric LT recipients. 
To replicate our findings we retrieved data from 317 adult 
and 185 pediatric European A iA T  deficient LT recipients. 
HCC was present in 24/317 adults (8%) and presence of 
HCC was associated with a poor 5 years survival (69% vs. 
83%, HCC patients vs non-HCC patients, p=o.oi).
The 15 years patient survival rates were 58% for adult LT 
recipients and 86% for pediatric LT recipients (p=o.ooi). 
The 15 years graft survival rates were 57% for adult LT 
recipients and 76% for pediatric LT recipients (p=o.o2). 
Conclusion: Patients with A iA T  deficiency induced cirrhosis 
are at high risk fo rthe development of HCC of which some 
were not recognized before LT. Presence of HCC predisposes 
for an inferior survival after LT.
Liver tra n s p la n ta tio n  and HCC in A1AT d e fic iency
Background
A lp h a-i antitrypsin (AiAT) deficiency is a genetic disorderthat most frequently 
presents as emphysema and less commonly as liver disease.1-2 In childhood, 
A iA T  deficiency liver disease presents as neonatal cholestasis which can lead 
to cirrhosis.The clinical phenotype of A iA T  deficiency in adults isthat of mild 
liver enzyme disturbances with or without advanced disease such as cirrhosis 
and hepatocellular carcinoma (HCC).1 Once diagnozed, most patients with liver 
cirrhosis in A iA T  deficiency will develop rapid progressive liverdisease.3 Atthat 
stage, the only curative approach is livertransplantation (LT).Theoretically, LT 
has a dual benefit, as it not only cures the liver disease but also restores A iA T  
serum levels by adopting the donor phenotype and thus offering protection 
against emphysem a.3 Most LT series are small and stem from the beginning of 
the livertransplantation era.They often have been performed in the pediatric 
population4-7 and originate from single centers. A recent series from the United 
Network for Organ Sharing (UNOS) database reported an excellent survival in 
A iA T  LT recipients.8
We investigated the clinical characteristics and prognosis after LT in both adult 
and pediatric patients with A iA T  deficiency. We addressed the following ques­
tions. First, we were interested in clinical characteristics of patients receiving 
LT for A iA T  deficiency. We hypothesized that the proportion of HCC cases would 
be low in A iA T  deficient LT recipients and we tested this hypothesis in 2 different 
cohorts. Secondly, benefiting from the comprehensive European LiverTrans- 
plantation Registry (ELTR) we examined patient and graft survival after LT.
Methods
Our study included 2 different cohorts. First, we studied the clinical charac­
teristics in a cohort of A iA T  deficient LT recipients in the Netherlands and 
secondly, we studied a cohort of LT patients with A iA T  deficiency that was 
submitted to the ELTR.
The Netherlands cohort
We analyzed the medical records of all adult and pediatric LT recipients with 
A iA T  deficiency who were transplanted from January 1985 onwards in all 3 LT 
centers in the Netherlands (University Medical Center Groningen, Erasmus
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Medical Center Rotterdam and Leiden University Medical Center). We used the 
local databases to identify LT recipients with A iA T deposits on explant histology, 
and were able to include 32 patients. We assessed patient demographics, date 
of i st presentation of liver disease, date of LT, date of last outpatient clinic visit, 
results of A iA T  iso-electrofocussing and A iA T  serum level quantification, 
spirometry: Forced Expiratory Volume in lse c/V ita l Capacity (FEVi/VC), histo­
logical report of the explant specimen, routine laboratory parameters, life style 
characteristics such as smoking and alcohol use, concomitant liver disease 
and causes and dates of re-transplantation or death. When HCC was present: 
size, number and alpha feto protein level.
ELTR cohort
We retrieved data collected in the ELTR to study patient and graft survival after 
LT for A iA T  deficiency in a large number of patients. The European Liver and 
Intestine Transplant Association (ELITA) board approved the study request 
and provided the data. We included patients who underwent LT from January 
i st 1993 to December 31st 2007 and who had A iA T  deficiency registered as 
primary disease or as associated disease. We excluded Dutch patients because 
these were studied in more detail in the first part of our study.
Statistics
Descriptive statistics were performed on baseline characteristics and presented 
as median and range. We used Mann-Whitney-U tests, Chi-square tests and 
Fisher exact tests where appropriate to analyze baseline characteristics. Odds 
Ratio's (OR) were calculated for gender distribution, presence of HCC, diabetes, 
smoking and alcohol history between patients with homozygous and hetero­
zygous disease in the Dutch cohort. In addition, we used OR's for calculating 
differences in baseline characteristics between adult and pediatric LT recipients 
in the ELTR cohort. For time-to-death or re-transplantation we applied the 
Kaplan-Meier method and compared groups using the log-rank test. All statis­
tical analyses were performed using GraphPad Prism Version 4.02 (GraphPad 
Software Inc., San Diego, CA, USA). Atwo-sided p-value of <0.05 was considered 
statistically significant.
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Results
The Netherlands cohort
We included 32 patients (24 adults and 8 pediatric LT recipients) who underwent 
LT from January i st 1985 until May 26th 2009. Pre-LT characteristics are given 
in table 8.1. One adult woman received auxiliary LT in 1987, the remaining 31 
patients were treated with standard orthotopic LT.
We detected HCC in 7 out of 24 (29%) adult LT recipients (71% males), and 
mean age (±SD) at diagnosis HCC was 50.6 (±10.3) years). The time between 
i st presentation of liver disease and LT was longer in adult LT recipients with 
HCC compared to adult LT recipients without HCC (p<o.01).(Figure 8.1)
Table 8.1: Pre-liver transplant characteristics of 24 adult and 8 pediatric LT recipients w ith 
a lp h a -i antitrypsin deficiency in the Netherlands
Adult n=24 Pediatric n=8
Median age at LT (yrs) (range) 50.6 (18.2-66.7) 7.1 (1.1-14.3)
Male (%) 19 (79%) 5 (63%)
Median ALT (lU/ml) (range) 53 (26-337) 124 (47-610)
Median bilirubin (umol/l) (range) 44 (9-800) 53 (10-266)
Median albumin (g/l) (range) 30 (16-44) 32 (18-41)
Prothrombin time (s) (range) 17 (11.8-25.3) 18(12.2-35.7)
FEV1/VC < 70% (%) (n=23) 6 (26%) NA
Diabetes 3 (13%) 0 (0%)
Time between 1st presentation of liver disease 
and LT (yrs) (range)
7.0 (0.5-27.5) 7.1 (0.9-14.14)
LT=Liver Transplantation; AlAT=alpha-l antitrypsin deficiency; FEV1/VC= Forced Expiratory Volume in 1 sec/Vital Capacity; 
NA=not available
Figure 8.1: Time interval between 1st presentation of liver disease and liver transplantation.
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Age at LT and age at first presentation of liver disease were similar in patients 
with and without HCC. In addition, other baseline characteristics (in particular 
presence of homozygous or heterozygous disease) were comparable for adult 
LT recipients with and without HCC. In all HCC cases the diagnosis was con­
firmed by histological examination of the surgical explant specimen. A total of 
4 out of 7 HCCs was not diagnozed prior to LT. These had an incidental HCC 
and had normal alpha feto protein levels (< io  ug/l) prior to LT. Two patients 
with incidental HCC had small single tum ors of 8 and 15 mm, 1 patient had 
multifocal H CCw iththe largerone m easuring30 mm and ip a tie n t had atum or 
measuring 80 mm. This tum or of 80 mm exceeded by far the Milan Criteria, 
though the patient was misclassified as having focal nodular hyperplasia prior 
to LT. All 3 patients with HCC who were recognized priorto LThad elevated alpha 
feto protein levels. We found no HCC in pediatric LT recipients, although one 
girl, transplanted at age 3.5 had a dysplastic node of 6 mm in her liver explant. 
A iA T  phenotyping was performed using iso-electrofocussing.The entire pop­
ulation of pediatric LT recipients was A iA T  homozygous and median serum 
level was 0.4 g/l (range: o.2-0.5 9 /0 - A iA T  phenotypes in 21 adult LT recipients 
were: 14 Pi ZZ (homozygous) and 5 Pi MZ, 1 Pi SZ and 1 Pi Mnull (heterozygous). 
Baseline characteristics were similar in homozygous and heterozygous adult 
LT recipients. A iA T  serum levels were lower in homozygous adults compared 
to heterozygous adults (median 0.3 g/l vs. 1.4 g/l, p=o.ooi). (Figure 8.2)
Figure 8.2: A lp h a -i antitrypsin serum levels in adult liver transplantation recipients with homozygous 
(Pi ZZ) and heterozygous (MZ or SZ) A iA T  deficiency.
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Spirometry results were available in 23 adult LT recipients but not for pediatric 
LT recipients. A total of 6/23 (26%) adult LT recipients had signs of obstructive 
pulmonary disease with FEVi/VC <0.7 prior to LT. One of these patients was a 
recipient of a simultaneous LT and unilateral lung transplant; this patient had 
increased spirometry results after transplantation.
Median time of follow-up was 5.3 years (range 0.1-24) ¡n adult and 3.4 years 
(range 0.7-16) in pediatric LT recipients. Five adults died after LT: due to cardiac 
disease (n=2, 21 and 2.5 years after LT), multi-organ-failure and in-hospital 
death (n=2, 0.1 and 0.4 years after LT) and metastatic melanoma (n= i, 6.4 
years after LT). Re-transplantation was performed in 2 adult LT recipients 
because of ischemic bile duct lesions 0.2 years after LT and liver failure of 
unknown origin at 3.4 years after LT. Three pediatric LT recipients, all trans­
planted in 1989, died. Reasons of death were sepsis (n=2, 1.7 and 2.6 years 
after LT) and pulmonary embolism (n=i, 16 years after LT).
ELTR cohort
As we observed an unexpected high frequency of HCC in our initial cohort 
we sought confirmation of this observation in an independent LT cohort. This 
replicative cohort comes from the ELTR database and we included 317 adult 
and 185 pediatric LT recipients, originating from 78 centers in 20 European 
countries. (See for complete list: addendum) A iA T  deficiency was registered 
as the leading indication for LT in 231 (73%) adult and 179 (97%) pediatric LT 
recipients and was registered as an associated disease in the remainder. The 
distribution in the absolute number of LT was bimodal, as we found a peak in 
early childhood and a second peak in middle-aged adults. (Figure 8.3)
We observed a male predominance in adult and pediatric LT recipients, but in 
adults this unbalanced gender distribution was more apparent (OR 1.8, 95%CI 
1.2-2.7). When corrected fo rth e  presence of alcoholic liver disease, the differ­
ence was not significant (OR 1.4, 95%CI 0.95-2.2). In adult LT recipients the 
registered associated diseases were different compared to pediatric LT recipi­
ents as concomitant alcoholic liver disease, HCC and cryptogenic cirrhosis 
were more frequently reported in adults and biliary atresia was unique to pe­
diatric LT recipients. (Table 8.2)
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Figure 8 .3 : A ge d is tr ib u t io n  am ong 502 p a tie n ts  w h o  u n d e rw e n t live r t ra n s p la n ta tio n  due to  a lp h a - i 
a n t it ry p s in  d e fic ien cy  b e tw e e n  1 9 9 3  and 2007 accord ing  to  th e  ELTR.
O
Age (yrs)
Table 8.2: Baseline characteristics of 502 patients, registered in the ELTR database, w ho underwent 
liver transplantation because of a lp h a -i antitrypsin deficiency between 1993 and 2007
Adult n=317 Pediatric n=185 OR (95% Cl)
Median age (range) 52.5 (18.7-70.4) 5.6 (0.3-17.1)
Male (%) 244 (77) 120(65) 1.8 (1.2-2.7) t
Associated diseases t(%)
HCC 24 (8) 1 (1 ) 15 (2.0-112) +
Alcoholic liver disease 65 (21) 0(0) NA
Cryptogenic cirrhosis 17 (5) 2 (1) 5.2 (1.2-22.7)t
Viral hepatitis 11 (3) 1 (1 ) 1.8 (0.18-17.0)
(Semi) Acute liver failure 2 (1) 1 (1 ) 1.2 (0.11-13.1)
AIH/PSC/PBC 6(2) 0(0) NA
Hemochromatosis 6(2) 0(0) NA
Polycystic liver disease 2 (1 ) 0(0) NA
Hemangioma 1(0 ) 0(0) NA
Tyrosemia°° 1(0) 0(0 ) NA
Biliary atresia 0(0) 6 (3) NA
Cystic Fibrosis 0(0) 1 (1 ) NA
^associated disease when A1AT deficiency was registered as indicator fo r LT and indicator fo r LT when A1AT deficiency 
was registered as associated disease. NA: not available, tstatistic significant. °°This patient was transplanted at age 20.
The 1-, 5-,io - and 15- year patient survival rates were 89%, 82%, 63% and 58% 
for adult LT recipients and 93%, 89%, 86% and 86% for pediatric LT recipients 
(p=o.ooi adult vs pediatric cohort).The 1-, 5-,10- and 15- year graft survival rates 
were 87%, 79%, 62% and 57% for adult LT recipients and 88%, 84%, 76% and 
76% for pediatric LT recipients (p=o.o2 adult vs pediatric cohort). (Figure 8.4)
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F igu re  8 .4 : P a t ie n t  su rv iva l (p anel A ) and g ra ft  su rv iva l (panel B) a fte r live r tra n sp la n ta tio n  in 502 
p a tie n ts  w ith  a lp h a - i a n titry p s in  d e fic ie n cy  registered  in the  E LTR .
----- Pediatric
—  Adult
Time (yrs)
-----Pediatric
—  Adult
Time (yrs)
The 1- and 5-year patients survival rates were 86% and 69% respectively in 
adults with HCC (n=24, 92% male) and 89% and 83% respectively in adults 
without HCC (n=293, 76% male). Therefore survival in patients without HCC 
was superior compared to patients with HCC (p=o.oi). (Figure 8.5) A total of 
9 adult LT recipients with HCC died after LT, the reason of death was tumor 
recurrence in 5 out of 9 (56%) patients.
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Discussion
This study shows a high rate of HCC in adult LT recipients due to A iA T  
deficiency as we found HCC in 29% of liver explants from an extensively 
phenotyped cohort of 32 patients. Some ofthese were unrecognized priorto 
LT (so-called incidental HCC). We confirmed these data in a larger replicative 
cohort and found that 24/317 (8%) had HCC in their explants. This series differs 
from other studies in the field as it adds several elements of novelty. First, 
we analyzed the frequency of HCC in a large number of LT patients with A iA T  
deficiency and second, we compared survival after LT in A iA T  deficient 
patients with and without HCC.
Literature is equivocal whether A iA T  deficiency represents a risk factor for 
HCC. Some studies indicate that HCC in patients with A iA T  deficiency is related 
to concom itant viral hepatitis9-11, others reported an association between 
HCC and the Z allele whereas others do not.12-14 The research strategies 
that these researchers have used to associate HCC with A iA T  deficiency 
are diverse. There have been a number of pathology studies that detected 
a higher incidence of A iA T  containing globules in HCC livers compared to 
control livers and epidem iology studies have studied whether A iA T  was a 
covariate factor for HCC on top of underlying disorders such as HBV or HCV.
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Both strategies come with disadvantages as they do not accurately estimate 
the prevalence of HCC in patients with A iA T  deficiency. Our study provides 
data that helps to address this issue. The high rate of HCC in our study is similar 
to that reported for genetic hemochromatosis (7/22, 32% ).15 We also show 
that survival rates after LT in A iA T  deficient adults with HCC are clearly inferior 
to those without HCC. Although these results are intuitive, the formal proof 
for this concept was absent from literature. LT recipients with HCC died due to 
tum or recurrence in 56% of cases. Earlier published guidelines did not recom­
mend for or against surveillance for HCC in A iA T  deficiency because a lack of 
data precluded an assessment of whether surveillance would be beneficial.16 
Our data have possible clinical implications as the risk for HCC in A iA T  deficiency 
appears to be real, although this cohort does not allow to provide an accurate 
estimate.
We found that the clinical course in adult LT recipients is similar in homozygous 
and heterozygous patients. Separate analysis did not yield different results 
with respect to gender, age at first presentation of liver disease, age at LT and 
concomitant alcohol abuse (data not shown). This was reason for us to lump 
these data together. All heterozygous A iA T  deficiency patients had serum 
levels > 1.0 g/l (thus in the normal range) and as a consequence, these patients 
could have been missed if only serum level quantification was performed. We 
previously showed that A iA T  serum levels were not suitable for the detection of 
heterozygous A iA T  deficiency in patients with chronic liver disease and sug­
gested to start the diagnostic path with iso-electrofocussing or genotyping.17 
The ELTR based part of our study shows that LT is a successful treatm ent for 
liver disease in A iA T  deficiency with excellent graft and patients' survival in 
adult and pediatric LT recipients. Both graft and patients' survival are superior 
in pediatric LT recipients compared to adult LT recipients.These results can be 
compared with the study that used the UNOS database to determine survival 
after LT in A iA T  deficiency. This study included 406 adult and 161 pediatric LT 
recipients who were transplanted between 1995 and 2004. The 1- and 5-year 
graft and patients survival in adult and pediatric LT recipients are sim ilarto our 
data.8 An earlier published study showed inferior results and reported a l-ye ar 
patient survival of 73% in adult and 88% in pediatric LT recipients.3The better
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survival in our cohort may be due to improvement in clinical care with tim e.18 
The superior LT results in pediatric patients relative to adults, is known to 
be true for other indications such as cholestatic disease and other metabolic 
diseases.18
The strength of our study is the replication of data from (1) a thorough analysis 
of clinical characteristics in patients with A iA T  deficiency who received LTinthe 
Netherlands by a second data set from (2) a large number of European patients 
with a long follow-up.The limitations of our study are asfollows: selection bias 
might be introduced as we only selected patients who received LT and therefore 
we cannot extrapolate our findings to all patients with A iA T  deficiency related 
liver disease. In addition, because of the retrospective design, there were 
missing data.
In conclusion: first, adult patients with end-stage liver disease due A iA T  
deficiency, requiring LT, are at risk for the development of HCC and some are 
not recognized prior to LT. Patients with HCC had inferior survival outcomes. 
Second, baseline characteristics were similar in patients with homozygous 
compared to heterozygous A iA T  deficiency. Third, this study showed that LT 
is an effective treatm ent of liver disease in A iA T  deficiency with excellent 
graft and patients' survival in adult and pediatric LT recipients.
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Addendum
Centres participating in the ELITA cohort study:
AUSTRIA:
BELGIUM:
Transplantationszentrum  A llegem eines Krankenhaus W ien, Prof. F Muhl bâcher; 
University H ospital-Dept of General & Transplant Surgery Innsbruck, Prof. R. 
M argreiter
C atholic University o f Louvain, Prof. J. de Ville de Goyet and Prof. J.Lerut; Hôpital 
Erasme, UL Bruxelles, Prof. V. Donkier; U niversity Hospital Ghent, Prof. B. de 
Hem ptinne; U niversity Hospital Leuvin, Dr. J. Pirenne; Domaine U niversitairer du 
SartT ilm an, Prof. M. Meurisse
CZECH REPUBLIC: Transplancenter Ikem Prague, Prof. S. Vitko 
DENM ARK: University Hospital Copenhagen, Prof. P. Kirkegaard
FINLAND: U.C.J. Helsingfors, Helsinki, Prof. K. Hockerstedt
FRANCE : CHU M arseille Hopital de la Conception, Prof. Y. Letreut ; Hopital Paul Brousse
Villejuif, Prof. D. Castaing ; CHU, Necker Paris Cedex, ProfY. Revillon ; CHRU de 
Strasbourg, Prof. D. Jaeck and Prof. P. Wolff; CHU Rennes, Prof. K. Boudjema; 
CHU de Besançon Hopital Jean Minjoz, Prof. G. Mantion; Hopital Beaujon, Prof.
J. Belghiti; Hopital de la Pitie Salpétriére Paris, Prof. L. Hannoun; Hopital E. 
Herriot Lyon, Prof. O. Bouillot; Hopital Henri M ondor Creteil, Prof. D. Cherqui; 
CHU Hopiteaux de Bordeaux, Prof. J. Saric; Hopital Pasteur Nice, Prof. A. Bourgeon
GERMANY: Medizinische Hochschule Hannover, Prof. J. Klempnauer; Klinikum der Universität
M ünchen-G rosshadern, Prof. R. Schauer; Charite- C am pus-Virchow  Klinikum 
Berlin, Prof. P. Neuhaus; Chirurgische Klinik und P o lik lin ik -K lin ik  rechts der Isar 
München, Prof. M. Stängel; U niversitatskrankenhaus Eppendorf Hamburg, Prof. 
X. Rogiers; Universitatsklinikum  Heidelberg, Prof.T. Kraus; Universitätsklinikum  
Schlesw ig-Holstein Kiel, Prof. B. Kremer; Klinikum der Universität zu Köln, Dr. D. 
Stippel; Universität Rostock-M edizinische Fakultät, Prof. W. Schareck; Univer- 
sitätsklin ikTübingen, Prof. A. Königsrainer and Prof. W. Steuer; CUK GHs Essen, 
Prof. C. Broelch; Universitätsklinikum  Münster, Prof. N. Senninger; U niversity of 
Bonn, Prof. M. Wolff; Johannes Gutenberg, Univ. Mainz Klinikum , Prof. G. Otto
GREAT BRITAIN: The Queen Elizabeth Hospital Birmingham, Prof. J. Buckels; Adenbrooke's Hospital 
Cam bridge, Mr. N. Jam ieson; Royal Infirm ary of Edinburgh, Prof. J.Garden; St 
Jame's & Seacroft University Hospital Leeds, Dr. S. Pollard; King's College Hospital 
London, Prof. J. O'Grady; Royal Free Hospital London, Dr. K. Rolles; The Freeman 
Hospital Newcastle, Mr. D. Manas
IRELAND: St Vincent Hospital Dublin, Prof. O. Traynor
ITALY: Centro Trapianti di Fegato Bari, Prof. V. Memeo; Ospedali Riuniti di Bergam o, Dr.
M. Colledan; Ospedale San Martino e Cliniche Universitarie Convenzionate Genova, 
Prof. U. Valente; Ospedale M aggiore Policlinico Milano, Prof. G. Rossi; Istituto di 
Chirurgia G enerale Padova, Prof. A. Maffei Faccioli; Instituto M editerraneo per i 
Trapianti e Terapie ad Alta Specializzazione Palermo, Prof D. d'Amico; Università 
Degli Studi di Roma, Prof. M. Rossi; University Hospital Udine, Prof. F. Bresadola
NORWAY: Rikshopitalet Oslo, Prof. A. Foss
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POLAND:
PORTUGAL:
ROMANIA:
SLOVENIA:
SPAIN:
SW EDEN:
SW ISS:
Children's M emorial Health Institute W arsaw, Dr. P. Kalicinski; Medical University 
of W arsaw, Prof. W. Rowinski
Hospitais da Univesidade de Coim bra, Prof. F. de Oliviera
University of Medicine "Carol Davila" Bucharest, Prof. I. Popescu
University Medical Centre Lubljana, Prof. S. M arkovic
Hospital Central de A sturias Oviedo, Dr. D. Gonzalez Pinto: Hospital Clinic I 
Provincial de Barcelona, Prof. J. G arcia-Valdecasas: Hospital Infantil Barcelona, 
Prof. V. M artinez Ibanez; Hospital Universitario "Reina Sofia" Cordoba, Prof. C. 
Pera; Hospital Juan Canalejo la Coruna, Dr. C. Fernandez Sellez; Hospital 12 de 
Octubre Madrid, Prof E. Moreno Gonzales; Hospital G regoria M aranon Madrid, 
Prof. C. Kempin; Hospital Infantil La Paz Madrid, Dr. J. Larrucea; Hospital Regional 
"Carlos Haya" Malaga, Prof. A. de la Fuente Perucho; Hospital Universitario Puerta 
de Hierro Madrid, Prof. V. SanchezTurrion; Clinica Universitaria Pamplona, Dr. F. 
Sanchez; Hospital Universitario "M arqués de Va Idecilla" Santander, Prof. L. Herrera 
Norena: Hospital Ntra Sra de Candelaria Santa Cruz deTenerife, Dr. A. Soriano; 
Hospital Universitario La Fe Valencia, Dr. J. Berenguer; Hospital de Cruces Vara- 
caldo-Vizcaya, Dr. J. Ortiz de Urbina; Hospital Clinico Universitario de Zaragoza, 
Dr. T. Serrano
Sahlgrenska University Hospital G oteborg, Dr. S. Friman; Huddinge Hospital,
Prof. B. Ericzon
U niversitatsspital Bern, Prof. D. Candinas; Hôpital Cantonal Universitaire de 
Geneve, Prof. P. Morel and Prof. G. Mentha; U niversitatspital Zurich, Prof. P. 
Clavien
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Chapter 9
General discussion
G eneral d iscussion
In 2005 a total of 3 patients presented with disturbed liver enzymes. They 
deteriorated rapidly and all died as a result of their liver disease. All 3 patients 
had normal serum levels of a lp h a -i antitrypsin (A iA T ) and the diagnosis 
A iA T  deficiency was only made by examination of a liver biopsy specimen. We 
discovered that all 3 patients were A iA T  deficient and heterozygous carriers 
ofthe Pi MZ allele.This was eventually confirmed with iso-electrofocussing. In 
hindsight, we relied too much on the "pseudo"- normal A iA T  levels and did 
not proceed to iso-electrofocussing or genotyping.1
These 3 cases spurred our interest in A iA T  deficiency as a cause of liver disease. 
We performed an extensive literature search that aimed to address the following 
questions.
First, we were interested in the clinical course ofthe disease. Do patients with 
A iA T  deficiency develop end-stage liver disease? What are the complications 
of A iA T  deficiency related liver disease? And what about the characteristics 
and prognosis of neonatal cholestasis due to A iA T  deficiency? We tried to find 
these answers and wrote a review ofthe current literature.2 Subsequently, we 
studied the clinical characteristics of neonates with cholestasis due to A iA T  
deficiency. We focused on prognosis and on bleeding complications due to 
vitamin K deficiency. Vitamin K deficiency is caused by cholestasis induced 
malabsorption. We detected a high proportion of vitamin K deficiency related 
bleeding, particularly in exclusively breast-fed infants.3 In addition, we studied 
clinical characteristics and prognosis after liver transplantation (LT) in adult 
and pediatric L.T recipients with A iA T  deficiency. We detected a high proportion 
of HCC in adult L.T recipients and the majority was diagnosed upon examination 
o fth e  explanted liver specimen. Indeed, A iA T  L.T recipients with HCC had an 
inferior survival compared to patients without HCC.
Second, we focused on the diagnostic approach for detecting A iA T  deficiency 
in liver disease. Guidelines and flow charts regarding the evaluation of A iA T  
deficiency proposed to start the initial evaluation with A iA T  serum level 
quantification and performing iso-electrofocussing or genotyping only in case 
serum level is decreased.4These flow charts are merely initiated by pulmonary 
centers. As serum levels >0.5 g/l represent a protective threshold above which 
the risk of emphysema is not increased, the cutoff point fits with the detection
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of A iA T  deficiency in pulmonary disease. Given that aberrant A iA T  phenotypes 
with serum levels above this protective threshold will not induce emphysema, 
the detection of an abnormal phenotype with a normal serum level is clinically 
less important for pulmonologists. In contrast, in the evaluation for hepatic 
disease the protective threshold is not the issue but abnormal phenotypes are 
relevant. We showed that the majority of liver patients with a heterozygous 
(Pi MZ) phenotype had serum levels above the cutoff value of 1.0 g/l. Addition­
ally, heterozygous (Pi MZ) A iA T  deficiency LT recipients had serum levels in 
the normal range. We concluded that relying on A iA T  serum levels alone, runs 
the risk of missing the right diagnosis.5
Third, other reports focused on associations between the Z allele and different 
liver diseases.The first reports describing associations between heterozygous 
A iA t deficiency and end-stage liver disease due to various etiologies were 
published in 1997 and 1998.6-7 In recent years a plethora of studies reported 
the results of the search for single nucleotide polym orphism s (SNPs) and 
associations with A iA T  deficiency.The topics which were studied can be divided 
into 2 groups. First, studies involving the relation between SNPs and the pheno­
type of homozygous (Pi ZZ) A iA T  deficiency. For example, the c.-igj3T>C  
polymorphism located in the 5ERPINAi promoter region (c.-igj3T>C ), appeared 
to be associated with neonatal liver disease compared to pulmonary disease 
in homozygous A iA T deficiency patients.8 Second, studies reporting SNPs in the 
SERPINAi gene and their association with different liver diseases. For example, 
a report showed an association between the Z allele in the SERPINAi gene 
and the presence of liver disease in cystic fibrosis patients.9 
We studied the association between the presence of heterozygous A iA T  
deficiency and treatm ent outcomes in hepatitis C virus infection.10 Further­
more, we performed a case-control study to detect an association between 
c.-ig73T>C  and liver disease of various etiologies. We could not show an 
association between treatm ent response among wild types and patients 
with heterozygous A iA T  deficiency and neither c.-ig j3T> C  was associated 
with liver disease of various etiologies.
All in all, these case- control genetic association studies require many patients 
and controls (mostly >500) to achieve statistical significant differences. When
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this large sample sizes are required for the detection of statistically significant 
differences, we question whether these findings are of major clinical relevance. 
Therefore, we addressed our fourth question. What is the clinical relevance 
of liver disease due to heterozygous A iA T  deficiency? We showed that the 
development of chronic liver disease due to heterozygous liver disease is a 
serious issue. Heterozygous disease can progress to end-stage liver disease and 
HCC requiring liver transplantation as well as homozygous A iA T  deficiency.11 
The studies described in this thesis might have clinical consequences as we 
hope that clinicians would be more aware of A iA T  deficiency as cause of liver 
enzyme disturbances and cirrhosis. In case of unexplained liver enzyme 
elevations or cryptogenic cirrhosis, diagnostic tests for A iA T  deficiency should 
be performed. To prevent under-diagnosis, they should start the diagnostic 
path with search for genetic mutations rather than quantify serum levels. 
In addition, the clinical picture of liver disease due to heterozygous A iA T  
deficiency is similar to homozygous A iA T  deficiency. Both heterozygous and 
homozygous A iA T  deficiency related liver disease can induce end-stage liver 
disease requiring livertransplantation. HCC isa common complication of liver 
disease in A iA T  deficiency; however the majority is so-called incidental. Our 
findings support surveillance for HCC in A iA T  deficient patients with liver 
disease, however the effect on survival still needs to be established.
Further research should aim at the detection of modifiers for the clinical 
phenotype of A iA T  deficiency. In other words: why do some patients develop 
liver disease, others develop pulmonary disease and do some A iA T  deficient 
subjects have no complications? Future investigation might follow research 
examples in cystic fibrosis, as the clinical expression of this hereditary disease 
is influenced by different genetic modifiers. For example, a recent study 
showed an association of CF transmembrane conductance regulator (CFTR) 
mutations and the presence of diabetes in cystic fibrosis.12
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Conclusion
Su m m ary and Conclusion
A lp h a-i antitrypsin (A iAT) deficiency is a genetic disorder which may lead to 
pulmonary and/or liver disease. In this thesis, the clinical consequences of A iA T  
deficiency are addressed. First, we described the clinical course of the disease; 
second the diagnostic pitfalls; third we focused on genetic associations and 
finally on the role of heterozygous A iA T  deficiency.
Chapter 1 is an introduction to A iA T  deficiency. The history of the detection of 
A iA T  deficiency and also the SERPINAi gene and the mutations involved in 
A iA T  deficiency are recorded. Furthermore, we provided an outline of the 
physiology of the normal M-type A iA T  and the pathophysiology of Z-type 
AiAT, which can lead to A iA T  deficiency. In addition we described the 
pathophysiologic mechanisms of liver and pulmonary disease. Chapter 2 is an 
overview of the literature regarding clinical consequences of A iA T  deficiency. 
The clinical presentation, diagnostic strategy, prognosis and therapy of A iA T  
deficiency related liver disease in children and adults are reviewed.
In chapter 3 and 4 studies in neonates with A iA T  deficiency are reported. 
In chapter 3, we studied the prognosis of neonatal cholestasis due to A iA T  
deficiency. We included all neonates who were born in the Netherlands 
between 1991 and 2006 and who were diagnosed with A iA T  deficiency in the 
first 3 months of life. We studied 50 neonates and 15 out of them presented 
with vitamin K deficiency bleeding. During follow-up, 5 patients (10%) died 
and 2 patients (4%) had to be transplanted. At the end of follow-up 12% had 
cirrhosis, 62% had liver enzyme abnormalities and/or hepato-splenomegaly 
and 12% had no signs of liver disease. Next, in chapter 4 we assessed the risk 
of vitamin K deficiency bleeding in neonates with cholestatic jaundice due 
to A iA T  deficiency. A total of 40 neonates were studied, 20 of them were 
breast-fed and received the recommended daily vitamin K prophylaxis and 20 
neonates were form ula-fed. Bleeding tendency was increased in breast-fed 
neonates compared to formula-fed neonates.
We performed 2 genetic association studies which are reported in chapter 5 
and 6. In chapter 5 we described the prevalence of the Z mutation in 2 cohorts 
of patients with hepatitis C virus infection (together 1,048 patients). We found 
a heterozygosity rate (Pi MS and Pi MZ) of 0.06, in line with healthy controls 
in other studies. Furthermore, we could not detect an association between S
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and Z allele mutations and sustained viral response after treatm ent with 
(PEG-)interferon and ribavirin. Additionally, in chapter 6 we reported the results 
of a study to investigatethe association betweenthe c.-igj3T>C  mutation inthe 
promoter region of the SERPINAi gene and liver disease of various etiologies. 
We included 297 patients and 297 controls, and performed real-time PCR for 
the c.-ig73T>C  mutation and Z and S allele. We could not demonstrate that 
c.-ig73T>C  polym orphism was a risk factor for liver disease due to various 
etiologies. However, S allele heterozygosity was increased in patients with 
drug induced liver injury and therefore, might contribute to its development. 
In chapter 7 we explored the diagnostic strategy for detection of A iA T  
deficiency. Testing for A iA T  deficiency in current practice starts with serum 
level quantification then followed by iso-electrofocussing or genotyping when 
the serum level is below a cut-off point of 1.0 g/l. We had the clinical impression 
that we missed liver disease patients with heterozygous A iA T  deficiency. 
Therefore, we studied A iA T  serum levels in 3 sets of heterozygous (Pi MZ) 
persons. We included 12 patients with liver disease due to various etiologies, 6 
patients with cirrhosis due to A iA T  deficiency and 15 controls. Serum levels 
were higher in patients with cirrhosis and liver disease of various etiologies 
compared to unaffected controls. The majority of heterozygous Pi MZ patients 
might be missed when we relied on serum level quantification alone.To prevent 
under diagnosis, we proposed starting the diagnostic path with iso-electrofocus- 
sing or PCR rat her than quantification of serum levels. In chapter 8, we assessed 
liver transplantation, the only curative treatment option in end-stage liver dis­
ease. We started with an analysis of the medical records of all patients who had 
received liver transplantation in the Netherlands. We detected a higher than 
expected prevalence of hepatocellular carcinoma in liver explant specimen: 
29% of adult liver transplantation recipients. We sought confirmation of this 
finding and studied data of livertransplantation recipients with A iA T  deficiency, 
collected in the European LiverTransplantation Registry. Similarly, we detected 
a high frequency of hepatocellular carcinoma. Furthermore we could dem on­
strate that hepatocellular carcinoma negatively affects outcome after liver 
transplantation. Moreover we showed that both homozygous and heterozygous 
A iA T  deficiency can be associated with end-stage liver disease.
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In conclusion: First, A iA T deficiency is a disorder with a low penetrance; however, 
in affected adults and children it is a serious issue and it can be associated with 
life-threatening complications. Second, to prevent under diagnosis we strongly 
suggest to start the diagnostic path with iso-electrofocussing or genotyping 
rather than serum level quantification. Finally, both heterozygous and homo­
zygous A iA T  deficiency can be associated with end-stage liver disease.
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Sam e n vattin g  en Conclusie
A lfa -i antitrypsine (AiAT) deficiëntie is een erfelijke aandoening die kan leiden 
tot zowel long- als leverziekte. In dit proefschrift proberen we de klinische 
consequenties van A iA T  deficiëntie te onderzoeken. Ten eerste hadden we 
vragen over het klinisch beloop van de ziekte, ten tweede over de diagnostische 
valkuilen, ten derde hebben we ons gericht op genetische associaties en ten 
slotte bogen we ons over de rol van heterozygote A iA T  deficiëntie.
Hoofdstuk i  is een inleiding in A iA T  deficiëntie. We beschreven de geschiedenis 
van het herkennen van A iA T  deficiëntie en tevens het SERPINAi gen en de 
mutaties die betrokken zijn bij A iA T  deficiëntie. We verklaren de fysiologie 
van het normale M-type A iA T  en de patho-fysiologie van het Z-type AiAT, 
welke kan leiden tot A iA T  deficiëntie. Daarnaast beschreven we de patho- 
fysiologische mechanismen van lever- en longaandoeningen. Hoofdstuk 2 is 
een overzicht van de literatuur met betrekking tot de klinische consequenties 
van A iA T  deficiëntie. De klinische presentatie, het diagnostisch traject, de 
prognose en de therapie van leverziekten door A iA T  deficiëntie bij kinderen 
en volwassenen komen in dit hoofdstuk aan bod.
In hoofdstuk 3 en 4 beschreven we de studies die we deden bij pasgeborenen met 
A iA T  deficiëntie. In hoofdstuk 3 rapporteerden we de prognose van neonatale 
cholestase door A iA T  deficiëntie. Wij includeerden alle pasgeborenen die zijn 
geboren in Nederland tussen 1991 en 2006 en bij wie A iA T  deficiëntie is vast­
gesteld in de eerste 3 maanden van het leven. We vonden 50 pasgeborenen 
met A iA T  deficiëntie en 15 van hen hebben zich initieel gepresenteerd met 
vitamine K deficiëntie afhankelijke bloedingen. Tijdens de follow-up zijn 5 
patiënten (10%) overleden en 2 patiënten (4%) moesten worden getrans­
planteerd. Aan het einde van de follow-up had 12% cirrose, 62% had afwijkende 
leverenzym en en/of hepato-splenom egalie en 12 % had geen tekenen van 
leverziekte. Vervolgens werd in hoofdstuk 4 het risico op vitamine K deficiëntie 
afhankelijke bloedingen bij pasgeborenen met cholestatische geelzucht als 
gevolg van A iA T  deficiëntie onderzocht. Er werden 40 pasgeborenen bestu­
deerd, 20 van hen kregen borstvoeding en ontvingen dagelijks de aanbevolen 
vitamine K profylaxe en 20 pasgeborenen kregen flesvoeding. Het risico op 
bloedingen was verhoogd bij pasgeborenen die borstvoeding kregen in verge­
lijking met pasgeborenen die flesvoeding kregen.
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Wij hebben 2 genetische associatie studies uitgevoerd die worden beschreven in 
hoofdstuk 5 en 6. In hoofdstuk 5 beschreven we een studie naar de prevalentie 
van de Z-mutatie in 2 cohorten van patiënten met hepatitis C virus infectie 
(samen 1048 patiënten). We vonden een heterozygotie prevalentie (Pi MS 
en Pi MZ) van 0.06, in overeenstemm ing met gezonde controles in andere 
studies. Bovendien konden we geen associatie ontdekken tussen S en Z alIel 
mutaties en therapiesucces 1 jaar na behandeling met (PEG-) interferon en 
ribavirine. Tevens onderzochten we in hoofdstuk 6 de associatie tussen de 
c.-i973T> C mutatie in de promotor regio van de SERPINAi gen en leverziekten 
door verschillende oorzaken. Wij bestudeerden 297 patiënten en 297 controles 
en we hebben real-time PCR verricht voor het vaststellen van de c.-igj3T> C 
mutatie en het Z en S-allel. We konden niet aantonen dat c.-ig j3T> C polymor- 
fisme een risicofactor is voor leverziekte door verschillende oorzaken. Echter, 
S allel heterozygositeit bleek vaker voor te komen bij patiënten met een 
geneesmiddel geïnduceerde leverschade, dit suggereert dat S allel hetero­
zygositeit zou kunnen bijdragen aan de ontwikkeling van door geneesmiddelen 
geïnduceerde leverziekten.
In hoofdstuk 7 gaan we nader in op het diagnostisch traject van A iA T deficiëntie. 
Sommige auteurs beargumenteren dat het testen op A iA T  deficiëntie zou 
moeten beginnen met het bepalen van een serumspiegel, gevolgd door iso- 
electrofocussing of genotypering als de serumspiegel kleiner is dan 1,0 g/l. We 
hadden klinisch de indruk dat we heterozygote leverpatiënten misten bij het 
volgen van die strategie. Daarom bestudeerden we A iA T  serum spiegels in 3 
groepen van heterozygote (Pi MZ) personen. Wij onderzochten 12 patiënten 
met een leverziekte door meerdere oorzaken, 6 patiënten met cirrose als 
gevolg van A iA T  deficiëntie en 15 controles. Serumspiegels waren hoger bij 
patiënten met cirrose en leverziekten door verschillende oorzaken vergeleken 
met controles. De meerderheid van de heterozygote Pi MZ patiënten zouden 
zijn gemist als we alleen serumspiegels hadden bepaald. Om het missen van 
de diagnose te voorkomen, stelden wij voor om het diagnostische traject te 
starten met iso-electrofocussing of PCR in plaats van het bepalen van serum ­
spiegels. In hoofdstuk 8 onderzochten we levertransplantatie bij patiënten 
met A iA T  deficiëntie, dit is de enige curatieve behandeling in het eindstadium
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van deze leverziekte. We begonnen met een analyse van de medische dossiers 
van alle patiënten die een levertransplantatie hadden ondergaan in Nederland. 
Tegen alle verwachtingen in, ontdekten we hepatocellulair carcinoom in 29% 
van de leverexplantaten bij volwassen. We zochten bevestiging van deze 
bevinding en bestudeerden vervolgens de gegevens van patiënten die een 
levertransplantatie moesten ondergaan wegens A iA T  deficiëntie, zoals deze 
verzameld waren in het Europese levertransplantatie register. Wij vonden ook 
in deze patiëntengroep een groot aantal hepatocellulair carcinomen. Daarnaast 
konden we aantonen dat patiënten met een hepatocellulair carcinoom een 
slechtere overleving hadden na levertransplantatie in vergelijking met patiënten 
zonder hepatocellulair carcinoom. Verder hebben we laten zien dat zowel 
homozygote als heterozygote A iA T  deficiëntie kan leiden tot eindstadium 
leverziekte.
Concluderend: Ten eerste, A iA T  deficiëntie is een aandoening met een lage 
penetrantie, echter bij aangedane kinderen en volwassenen is het een serieus 
probleem en het kan leiden tot levensbedreigende complicaties. Ten tweede, 
om het missen van de diagnose te voorkomen adviseren wij om het diagnostisch 
traject te starten met iso-electrofocussing of genotypering in plaats van het 
bepalen van serumspiegels. Ten slotte, zowel heterozygote als homozygote 
A iA T  deficiëntie kan leiden tot eindstadium leverziekte.
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Dankwoord
Het project dat in dit proefschrift wordt beschreven is in meerdere fases ver­
richt. Tijdens de opleiding tot MDL-arts leek het op een dieseltreintje dat op 
elk stationnetje stopt en hortend en stotend steeds weer verder gaat. Na het 
afronden van de opleiding, mocht ik in de "kelder", in alle rust, ver weg van de 
kliniek, plaatsnemen tussen de onderzoekers. Daar kreeg het project het tempo 
van een Intercity, vervolgens ging de trein steeds harder rijden en werd in de 
laatste maanden een echte HSL. Daardoor kon het eindstation worden bereikt 
voordat ik in het Canisius Wilhelmina Ziekenhuis ging starten als MDL-arts.
Het afronden van het promotietraject was niet mogelijk geweest zonder de 
hulp van velen.
Beste professor dr. JPH Drenth, beste Joost,
Hoeveel dankwoorden kan ik op papier zetten? Eén ding is zeker, zonder jou 
was het dieseltreintje geen intercity geworden en was het eindstation nimmer 
bereikt. Ik heb genoten van onze wekelijkse bijeenkomsten die inspirerend en 
leerzaam waren. Je opmerkingen bij teksten waren sporadisch ontm oedi­
gend, soms grappig ("dame, wat doet deze zin hier?"), meestal helder en altijd 
leerzaam.
Beste dr. MGH van Oijen, beste Martijn,
In de fase dat dit project als dieseltreintje reed, was jij degene die de motor 
soms iets extra brandstof gaf zodat het bleef rijden. Nadat ik bij jou in de 
"kelder" kwam wonen, heb je je over het project ontfermd en ben je een steeds 
grotere rol gaan spelen. Ik ben er trots op dat ik je eerste (co)promovendus 
ben, velen zullen volgen.
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Beste dr. RA de Vries, beste Richard,
Ik wil je danken voor je wijze, klinische lessen. Dank voor het feit dat je me 
hebt gestimuleerd om dit promotietraject te starten. Je hebt het onderzoek 
dat in dit proefschrift staat beschreven op de rails gezet.
Beste professor dr. JBMJ Jansen, beste Jan,
Dank voor het "warme nest" datje als afdelingshoofd wist te bieden aan artsen 
en onderzoekers. Jij komt echt op voor je mensen. Ik heb het gewaardeerd dat 
ik na het beëindigen van de opleiding tot MDL-arts het onderzoeksproject kon 
afronden.
Daarnaast hebben vele anderen een rol gespeeld bij het tot stand komen van 
dit proefschrift.
Beste Roderick, Peter en Lotte (Wilhelmina Kinderziekenhuis Utrecht), ik wil 
jullie bedanken voor de prettige samenwerking bij de studies bij kinderen met 
a lp h a-i antitrypsine deficiëntie.
Greet en Hanneke (ook Utrecht) bedankt voor jullie bijdrage aan de studie 
bij hepatitis C patiënten. De phenotyperingen zijn verricht in het Rijnstate 
Ziekenhuis te Arnhem doorTeun, Frans en Yvonne: dank voor het analyseren 
van de vele monsters.
Ik heb met veel plezier gewerkt op het "Lab Gastro" in het Radboud: René, 
Hennie, Jannes en W ilbert bedankt. René, dank voor het ontwerpen van 
de primers en probes; ik heb vol bewondering toegekeken hoe jij mijn 
Excel-bestanden onderhanden nam waarna er allerlei mogelijke variaties en 
associaties uit de computer kwamen rollen.
Dank aan de collega's afkomstig uit Groningen, Rotterdam en Leiden die 
gegevens beschikbaar stelden zodat de studie naar de uitkomst van lever- 
transplantatie bij ap h a-i antitrypsine deficiëntie verricht kon worden.
D ankw oord
Petra, dank voor je hulp en voor de gezelligheid onderweg bij het doorkruizen 
van het land op zoek naar statussen. Ook de zoektocht naar diepgevroren 
monsters op een donkere zolder zal ik niet snel vergeten.
Janneke, wat heb je er een mooi boekje van gemaakt, bedankt.
Mijn keldergenoten Serena, Mieke en Merel, jullie waren prettige collega's, 
maar wat voelde ik me soms oud als we op maandagochtend het weekend 
doornamen.
Daarnaast wil ik dank uitspreken aan alle klinische collega's uit het UMC St 
Radboud: Nynke, Eric,Tessa, Aura, Roland, Manon,Tanya, Joris, Marije, Bertram, 
Marriëtte, Dirk, Geert en Fokko, ik heb veel van jullie geleerd.
Mijn collega's in de maatschap internisten / MDL van het CWZ en in het bijzonder 
Adriaan, Ellen en Nieves: dank voor de prettige samenwerking.
Promoveren is vaak organiseren, ook thuis moest het (en moet het nog steeds) 
vlotjes lopen. Dank aan iedereen die hulp biedt bij het oppassen en huishouden.
Dan mijn paranimfen, Annemieke en Maureen. Onze vriendschap is ontstaan 
in de m entorgroeptijdens de introductieweek in 1994; nu 16 jaar later hebben 
we alle 3 onze plek in het medische veld gevonden. Annemieke en Maureen 
dank voor jullie steun tijdens de lastige momenten in het promotietraject.
Mijn ouders, jullie hebben ons (Dennis, Ivo en mij) altijd gesteund om het beste 
uit onszelf te halen. Jullie lieten ons zien dat er meer bestond dan het prachtige 
Twente en stimuleerden ons om ons eigen pad te kiezen.
Familie en vrienden, dank voor de gezelligheid en voor de belangstelling voor 
het onderzoek.
En dan als laatste, Martin en Lisa, jullie zijn m ijnthuis. Lieve, kleine Lisa, mama 
houdt van jou en zal nu niet meer gaan computeren op jouw  "mama-dagen".
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